|
(11) | EP 1 049 700 B9 |
| (12) | CORRECTED EUROPEAN PATENT SPECIFICATION |
| Note: Bibliography reflects the latest situation |
|
|
| (54) |
CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR CHEMOKIN REZEPTOR ANTAGONISTEN UND VERWNDUNG ANTAGONISTES DU RECEPTEUR DE CHEMOKINE ET LEURS PROCEDES D'UTILISATION |
|
|
|||||||||||||||||||||||||||||||
| Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). |
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. Serial No. 09/148,823, filed September 4, 1998, which is a continuation-in-part of U.S. Serial No. 09/010,320, filed January 21, 1998, now abandoned.
BACKGROUND OF THE INVENTION
[0002] Chemoattractant cytokines or chemokines are a family of proinflammatory mediators that promoce recruitment and activation of multiple lineages of leukocytes and lymphocytes. They can be released by many kinds of tissue cells after activation. Continuous release of chemokines at sites of inflammation mediates the ongoing migration of effector cells in chronic inflammation. The chemokines characterized to date are related in primary structure. They share four conserved cysteines, which form disulfide bonds. Based upon this conserved cysteine motif, the family is divided into two main branches, designated as the C-X-C chemokines (α-chemokines), and the C-C chemokines (β-chemokines), in which the first two conserved cysteines are separated by an intervening residue, or adjacent respectively (Baggiolini, M. and Dahinden, C. A., Immunology Today, 15:127-133 (1994)).
[0003] The C-X-C chemokines include a number of potent chemoattractants and activators of neutrophils, such as interleukin 8 (IL-8), PF4 and neutrophil-activating peptide-2 (NAP-2). The C-C chemokines include RANTES (Regulated on Activation, Normal T Expressed and Secreted), the macrophage inflammatory proteins 1α and 1β (MIP-1α and MIP-1β), eotaxin and human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2, MCP-3), which have been characterized as chemoattractants and activators of monocytes or lymphocytes but do not appear to be chemoattractants for neutrophils. Chemokines, such as RANTES and MIP-1α, have been implicated in a wide range of human acute and chronic inflammatory diseases including respiratory diseases, such as asthma and allergic disorders.
[0004] The chemokine receptors are members of a superfamily of G protein-coupled receptors (GPCR) which share structural features that reflect a common mechanism of action of signal transduction (Gerard, C. and Gerard, N.P., Annu Rev. Immunol., 12:775-808 (1994); Gerard, C. and Gerard, N. P., Curr. Opin. Immunol., 6:140-145 (1994)). Conserved features include seven hydrophobic domains spanning the plasma membrane, which are connected by hydrophilic extracellular and intracellular loops. The majority of the primary sequence homology occurs in the hydrophobic transmembrane regions with the hydrophilic regions being more diverse. The first receptor for the C-C chemokines that was cloned and expressed binds the chemokines MIP-1α and RANTES. Accordingly, this MIP-1α/RANTES receptor was designated C-C chemokine receptor 1 (also referred to as CCR-1; Neote, K., et al., Cell, 72:415-425 (1993); Horuk, R. et al., WO 94/11504, May 26, 1994; Gao, J.-I. et al., J. Exp. Med., 177:1421-1427 (1993)). Three receptors have been characterized which bind and/or signal in response to RANTES: CCR3 mediates binding and signaling of chemokines including eotaxin, RANTES, and MCP-3 (Ponath et al., J. Exp. Med., 183:2437 (1996)), CCR4 binds chemokines including RANTES, MIP-1α, and MCP-1 (Power, et al., J. Biol. Chem., 270:19495 (1995)), and CCR5 binds chemokines including MIP-1α, RANTES, and MLP-1β (Samson, et al., Biochem. 35: 3362-3367 (1996)). RANTES is a chemotactic chemokine for a variety of cell types, including monocytes, eosinophils, and a subset of T-cells. The responses of these different cells may not all be mediated by the same receptor, and it is possible that the receptors CCR1, CCR4 and CCR5 will show some selectivity in receptor distribution and function between leukocyte types, as has already been shown for CCR3 (Ponath et al.). In particular, the ability of RANTES to induce the directed migration of monocytes and a memory population of circulating T-cells (Schall, T. et al., Nature, 347:669-71 (1990)) suggests this chemokine and its receptor(s) may play a critical role in chronic inflammatory diseases, since these diseases are characterized by destructive infiltrates of T cells and monocytes.
[0005] Many existing drugs have been developed as antagonists of the receptors for biogenic amines, for example, as antagonists of the dopamine and histamine receptors. No successful antagonists have yet been developed to the receptors for the larger proteins such as chemokines and csa. Small molecule antagonists of the interaction between C-C chemokine receptors and their ligands, including RANTES and MIP-1α, would provide compounds useful for inhibiting harmful inflammatory processes "triggered" by receptor ligand interaction, as well as valuable tools for the investigation of receptor-ligand interactions.
SUMMARY OF THE INVENTION
[0006] It has now been found that a class of small organic molecules are antagonists of chemokine receptor function and can inhibit leukocyte activation and/or recruitment. An antagonist of chemokine receptor function is a molecule which can inhibit the binding and/or activation of one or more chemokines, including C-C chemokines such as RANTES, MIP-1α, MCP-2, MCP-3 and MCP-4 to one or more chemokine receptors on leukocytes and/or other cell types'. As a consequence, processes and cellular responses mediated by chemokine receptors can be inhibited with these small organic molecules. Based on this discovery, the molecules can be used in the treatment of a disease associated with aberrant leukocyte recruitment and/or activation and also in the treatment of a disease mediated by chemokine receptor function. The claimed compounds can be administered to a subject in need an effective amount of a compound or small organic molecule which is an antagonist of chemokine receptor function. Compounds or small organic molecules which have been identified as antagonists of chemokine receptor function are discussed in detail hereinbelow, and can be used for the manufacture of a medicament for treating or for preventing a disease associated with aberrant leukocyte recruitment and/or activation. The invention also relates to the disclosed compounds and small organic molecules for use in treating or preventing a disease associated with aberrant leukocyte recruitment and/or activation. The invention also includes pharmaceutical compositions comprising one or more of the compounds or small organic molecules which have been identified herein as antagonists of chemokine function and a suitable pharmaceutical carrier. The invention further relates to novel compounds which can be used to treat an individual with a disease associated with aberrant leukocyte recruitment and/or activation.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007]
Figure 1 is a schematic showing the preparation of the compounds represented by Structural Formula (I).
Figure 2 is a schematic showing the preparation of the compounds represented by Compound (VI-b).
Figure 3 is a schematic showing the preparation of the compounds represented by Structural Formula (I)
Figure 4 is a schematic showing the preparation of the compounds represented by Structural Formula (I), wherein Z is represented by Structural Formula (II) and wherein Ring A and/or Ring B in Z is substituted with R40.
Figure 5 is a schematic showing the preparation of the compounds represented by Structural Formula (I), wherein Z is represented by Structural Formula (II) and wherein Ring A and/or Ring B in Z is substituted with -(O)u-(CH2)t-COOR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20.
Figures 6A-6Z show the structures of exemplary compounds of the present invention as well as other compounds which fall outside the present invention.
Figure 7 shows the preparation of compounds represented by Structural Formula (I) where in Z is represented by Structural Formulas (II) and wherein Ring A or Ring B in Z is substituted with R40.
DETAILED DESCRIPTION OF THE INVENTION
[0008] The present invention relates to small molecule compounds which are modulators of chemokine receptor function. The compounds of the invention are suitable for use in the treatment of the human or animal body by therapy. In a preferred embodiment, the small molecule compounds are antagonists of chemokine receptor function.
[0009] Accordingly, processes or cellular responses mediated by the binding of a chemokine to a receptor can be inhibited (reduced or prevented, in whole or in part), including leukocyte migration, integrin activation, transient increases in the concentration of intracellular free calcium [Ca++]i, and/or granule release of proinflammatory mediators.
[0010] The invention further relates to the use of the claimed compounds in the manufacture of a medicament for treating, including prophylactically and therapeutically treatments, a disease associated with aberrant leukocyte recruitment and/or activation or mediated by chemokines or chemokine receptor function, including chronic inflammatory disorders characterized by the presence of RANTES, MIP-1α, MCP-2, MCP-3 and/or MCP-4 responsive T cells, monocytes and/or eosinophils, including but not limited to diseases such as arthritis (e.g., rheumatoid arthritis), atherosclerosis, arteriosclerosis, ischemia/reperfusion injury, diabetes mellitus (e.g., type 1 diabetes mellitus), psoriasis, multiple sclerosis, inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, rejection of transplanted organs and tissues (i.e., acute allograft rejection, chronic allograft rejection), graft versus host disease, as well as allergies and asthma. The compounds of the invention are particularly useful in the manufacture of medicaments for treating arthritis or multiple sclerosis. Other diseases associated with aberrant leukocyte recruitment and/or activation which can be treated (including prophylactic treatments) with the compounds disclosed herein are inflammatory diseases associated with Human Immunodeficiency Virus (HIV) infection, e.g., AIDS associated encephalitis, AIDS related maculopapular skin eruption, AIDS related interstitial pneumonia, AIDS related enteropathy, AIDS related periportal hepatic inflammation and AIDS related glomerulo nephritis. An effective amount of a claimed compound (i.e., one or more compounds) which inhibits chemokine receptor function, inhibits the binding of a chemokine to leukocytes and/or other cell types; and/or which inhibits leukocyte migration to, and/or activation at, can be administered at to a subject is need of treatment at sites of inflammation.
[0011] The invention further relates to use of the claimed compounds in the manufacture of a medicament for antagonizing a chemokine receptor, such as CCR1. Such medicaments can be administered to a mammal as described herein.
[0012] By administering such a medicament, chemokine-mediated chemotaxis and/or activation of pro-inflammatory cells bearing receptors for chemokines can be inhibited. As used herein, "pro-inflammatory cells" includes but is not limited to leukocytes, since chemokine receptors can be expressed on other cell types, such as neurons and epithelial cells.
[0013] While not wishing to be bound by any particular theory or mechanism, it is believed that compounds of the invention are antagonists of the chemokine receptor CCR1, and that therapeutic benefits derived from the method of the invention are the result of antagonism of CCR1 function. Thus, compounds of the invention can be used to treat a medical condition involving cells which express CCR1 on their surface and which respond to signals transduced through CCR1, as well as the specific conditions recited above.
[0014] In one embodiment, the antagonist of chemokine receptor function is represented by Structural Formula (I):
and physiologically acceptable salts thereof.
[0015] Z is
wherein:
X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, S-CH2-, -O-CH2-, -CH2-O-, -NRc-CH2-, -CH2-NRc-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NRc-CO- or -CO-NRc-;
Rc is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group;
Ring A and Ring B are independently substituted or unsubstituted; said substituted aliphatic group comprises one or more substituents selected from the group consisting of an electron withdrawing group, halo, azido, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group), -Q-(substituted aromatic group), -Q-(CH2)p-(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic group), -Q-(CH2)p-(non-aromatic heterocyclic group), aliphatic group and substituted aliphatic group; said substituted non-aromatic heterocyclic group comprises one or more substituents selected from the group consisting of an electron withdrawing group, halo, azido, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group), -Q-(substituted aromatic group), -Q-(CH2)p-(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic group), -Q-(CH2)p-(non-aromatic heterocyclic group), aliphatic group, substituted aliphatic group, =O, =S, =NH, =N(aliphatic), =N(aromatic) and =N(substituted aromatic);
R20, R21 and R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or -NHC(O)-O-(non-aromatic heterocyclic group); or
R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
t is an integer from zero to three;
u is zero or one;
p is one to five;
Q is -O-, -S-, -S(O)-, -S(O)2-, -OS(O)2-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)C(O)-O-, -O-C(O)C(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -NH-C(O)-NH-, -S(O)2NH-, -NHS(O)2-, -N(R23)-, -C(NR23)NHNH-, -NHNHC(NR23)-, -NR24C(O)- or -NR24S(O)2-;
R23 is -H, an aliphatic group, a benzyl group, an aryl group or non-aromatic heterocyclic group;
R24 and R25 are independently -H, -OH, an aliphatic group, a substituted aliphatic group, a benzyl group, an aryl group or non-aromatic heterocyclic group;
said aliphatic group is a saturated or unsaturated C1-C20 hydrocarbon;
said electron withdrawing group is alkylamino, alkylsulfonyl, carboxamido, carboxylic alkyl ester, -CH=NH or -NO2;
the heterocycle of said non-aromatic heterocyclic group is a 5 to 8 membered non-aromatic ring that contains one or more heteroatoms selected from the group consisting of O, N, and S; and
said aromatic group is selected from the group consisting of a C6 aromatic carbocycle, a C5 - C6 aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of O, S and N, and a C6 aromatic carbocycle or a C5 - C6 aromatic heterocycle that is fused to one or more other rings.
n is an integer from one to four. Preferably, n is one; two or three. More preferably n is two.
M is >CR1R2. M is preferably >C(OH)R2.
R1 is -H, -OH, an aliphatic group, -O- (aliphatic group), -O- (substituted aliphatic group), -SH, -S- (aliphatic group), -S- (substituted aliphatic group), -OC(O)-(substituted aliphatic group), -C(O)O- (aliphatic group), -C(O)O- (substituted aliphatic group), -COOH, -CN, -CO-NR3R4, -NR3R4; or R1 can be a covalent bond between the ring atom at M and an adjacent carbon atom in the ring which contains M. R1 is preferably -H or -OH.
R2 is -OH, an acyl group, substituted acyl group, -NR5R6, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group. R2 is preferably an aromatic group or a substituted aromatic group. Preferably R2 is an aromatic group substituted with halogen, for example a 4-chlorophenyl group.
R3, R4, R5 and R6 are independently -H, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group. The term acyl group represents an aliphatic carbonyl, aromatic carbonyl, aliphatic sulfonyl or aromatic sulfonyl.
[0016] In some embodiments, R1 and R2, R3 and R4, or R5 and R6 taken together with the atom to which they are bonded, can alternatively form a substituted or unsubstituted non-aromatic heterocyclic ring.
[0017] In some embodiments the methylene group, -(CH2)t-, can be substituted or unsubstituted. In embodiments where M is >CR1R2 and R1 is a covalent bond between the carbon atom at M and an adjacent carbon atom in the ring which contains M, the antagonist of chemokine function can be represented by Structural Formula (Ia).
Z, n and R2 are as described in Structural Formula (I).
[0018] According to a different embodiment of the invention there is provided a compound of formula:
or physiologically acceptable salt thereof, wherein:
n is an integer from one to four;
M is >CR1R2
R1 is -H, -OH, an aliphatic group, -O-(alipharic group), -O-(substituted aliphatic group), -SH, -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group), -O-C(O)-(substituted aliphatic group), -C(O)O-( aliphatic group), -C(O)O-(substituted aliphatic group), -CN, -COOH, -CO-NR3R4 or -NR3R4;
R2 is -OH, an acyl group, a substituted acyl group, -NR5R6, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
R3, R4, R5 and R6 are independently -H, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; or
R1 and R2, R3 and R4, or R5 and R6 taken together with the atom to which they are bonded, form a substituted or unsubstituted non-aromatic carbocyclic or heterocyclic ring;
said acyl group is an aliphatic carbonyl, aromatic carbonyl, aliphatic sulfonyl or aromatic sulfonyl;Z is:
wherein:
X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NRc-CH2-, -CH2-NRc-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NRc-CO- or -CO-NRc- ;
Rc is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group;
Ring A and Ring B are independently substituted or unsubstituted;said substituted aliphatic group comprises one or more substituents selected from the group consiting of an electron withdrawing group, halo, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, - S(O)2NH2, guamdino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-C(O)-NR21R22, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(CH2)p-(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic group),
-Q-(CH2)p-(non-aromatic heterocyclic group), oxo, epoxy, non-aromatic heterocycle, benzyl, substituted benzyl, aromatic group and substituted aromatic group;
said substituted benzyl group, substituted aromatic group, and Ring A or Ring B when substituted comprise one or more substitutents selected from the group consisting of an electron withdrawing group, halo, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-C(O)-NR21R22, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(CH2)p-(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic group),
-Q-(CH2)p-(non-aromatic heterocyclic group), aliphatic group and substituted aliphatic group;
said substituted non-aromatic heterocyclic group comprises one or more substitutents selected from the group consisting of an electron withdrawing group, halo, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-C(O)-NR21R22,
-Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(CH2)p-(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic group), -Q-(CH2)p-(non-aromatic heterocyclic group), aliphatic group, substituted aliphatic group, =O, =S, =NH, =N(aliphatic), =N(aromatic) and =N(substituted aromatic);
R20, R21 and R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or -NHC(O)-O-(non-aromatic heterocyclic group); or
R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
t is an integer from zero to three;
u is zero or one;
p is one to five;
Q is -O-, -S-, -S(O)-, -S(O)2-, -OS(O)2-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)C(O)-O-, -O-C(O)C(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -NH-C(O)-NH-, -S(O)2NH-, -NHS(O)2-, -N(R23)-, -CNR23)NHNH-, -NHNHC(NR23)-;
R23 is -H, an aliphatic group, a benzyl group, an aryl group or non-aromatic heterocyclic group;
said aliphatic group is a saturated or unsaturated C1-C20hydrocarbon;
said electron withdrawing group is alkylimino, alkylsulfonyl, carboxamido, carboxylic alkyl ester, -CH=NH or -NO2;
the heterocycle of said non-aromatic heterocyclic group is a 5 to 8 membered non-aromatic ring that contains one or more heteroatoms selected from the group consisting of O, N, and S; and
said aromatic group is selected from the group consisting of a C6 aromatic carbocycle, a C5 - C6 aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of O, S and N, and a C6 aromatic carbocycle or a C5 - C6 aromatic heterocycle that is fused to one or more other rings.
[0019] In this embodiment, compounds are preferred wherein:
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH, -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group) or -O-C(O)-(substituted aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is:
wherein:
X1 is -CH2-CH2-, -CH2-S-, -CH2-O-, -CH2-NRc-, -CH2-SO-, -CH2-S(O)2-, -CH=CH- or -CO-NRc- ; wherein:
Rc is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group; and
Ring A and Ring B are independently substituted or unsubstituted. It is preferred that R1 is -OH and R2 is a substituted or unsubstituted aromatic group. Preferably R2 is 4-chlorophenyl.[0020] As discussed above, in all embodiments of the present invention Z is represented by Structural Formula (II):
[0021] The phenyl rings in Structural Formula (II), labelled with an "A" and "B", are referred to herein as "Ring A" and "Ring B", respectively. The central ring, labelled with a "C", is referred to as "Ring C".
[0022] Ring A and/or Ring B in Structural Formula (II) can be unsubstituted. Alternatively, Ring A and/or Ring B can have one or more substituents. Suitable substituents are as described hereinbelow. In one example, Ring A or Ring B is substituted with -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20.
[0024] Preferably Ring B is substituted with -OH, halo, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20; wherein:
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or
R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
u is zero or one; and
t is an integer from zero to three.
[0025] In a preferred embodiment, Ring B in Structural Formula (II) is substituted para to the carbon atom of Ring B which is bonded to X1 of Ring C, and Z is represented by Structural Formula (III):
wherein:
R40 is -OH, halogen, aliphatic group, substituted aliphatic group, -NR24R25, Q-(aliphatic group), Q-(substituted aliphatic group), -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)OR20;
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or
R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
Q is -NR24C(O)- or -NR24S(O)2-;
R24 and R25 are independently -H, -OH, an aliphatic group or a substituted aliphatic group;
u is zero or one; and
t is an integer from zero to 3.
[0026] X1 can be as described above in Structural Formula (II). Preferably X1 is -CH2-O-, -CH2-CH2- or -CH2-S-.
[0027] Preferably R40 is an aliphatic group, substituted aliphatic group, -O- (aliphatic group) or -O- (substituted aliphatic group). More preferably R40 is an -O-alkyl, such as -O-CH3, -O-C2H5, -O-C3H7 or -O-C4H9. More preferably R40 is -O-CH3.
[0028] Another embodiment of the present invention includes novel compounds employed in these methods.
[0029] The compounds disclosed herein can be obtained as E- and Z-configurational isomers. It is expressly pointed out that the invention includes compounds of the E-configuration and the Z-configuration around the double bond connecting Ring C of Z to the remainder of the molecule, and a method of treating a subject with compounds of the E-configuration, the Z-configuration, and mixtures thereof. Accordingly, in the structural formulas presented herein, the symbol:
is used to represent both the E-configuration and the Z-configuration. Preferably Ring A and the alkylene chain bonded to Ring C are in the cis configuration. For example, the compounds can have the configuration of:
[0030] It is understood that one configuration can have greater activity than another. The desired configuration can be determined by screening for activity, employing the methods described herein.
[0031] Additionally, certain compounds of the invention may be obtained as different sterioisomers (e.g., diastereomers and enantiomers). It is pointed out that the invention includes all isomeric forms and racemic mixtures of the disclosed compounds and a method of treating a subject with both pure isomers and mixtures thereof, including racemic mixtures. Again, it is understood that one sterioisomer may be more active than another. The desired isomer can be determined by screening.
[0032] Also included in the present invention are physiologically acceptable salts of the compounds represented by Structural Formula (I) above Salts of compounds containing an amine or other basic group can be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, citric acid, perchloric acid and the like. Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base, for example, a hydroxide base. Salts of acidic functional groups contain a countercation such as sodium, potassium, ammonium, calcium and the like.
[0033] As used herein, aliphatic groups include straight chained, branched or cyclic C1-C20 hydrocarbons which are completely saturated or which contain one or more units of unsaturation. For example, suitable aliphatic groups include substituted or unsubstituted linear, branched or cyclic C1-C20 alkyl, alkenyl or alkynyl groups.
[0034] Aromatic groups include carbocyclic aromatic groups such as phenyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl, and heterocyclic aromatic or heteroaryl groups such as N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-pyrazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 5-tetrazolyl, 2-oxazolyl, 4-oxazolyl and 5-oxazolyl. Where these rings are fused, for example, to Ring C, the stated point of attachment can be either of the two fused bonds.
[0035] Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other rings. Examples include tetrahydronaphthyl, 2-benzothienyl, 3-benzothienyl, 2-benzofuranyl, 3-benzofuranyl, 2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzooxazolyl, 2-benzimidazolyl, 2-quinolinyl, 3-quinolinyl, 1-isoquinolinyl, 3-quinolinyl, 1-isoindolyl, 3-isoindolyl, acridinyl, 3-benzisoxazolyl, and the like.
[0036] Also included within the scope of the term "aromatic group", as it is used herein, is a group in which one or more carbocyclic aromatic rings and/or heteroaryl rings are fused to a cycloalkyl or non-aromatic heterocyclic ring, for example, benzocyclopentane, benzocyclohexane.
[0037] Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring. The ring can be five, six, seven or eight-membered and/or fused to another ring, such as a cycloalkyl on aromatic ring. Examples include 3-1H-benzimidazol-2-one, 3-1-alkylbenzimidazol-2-one, 3-1-methyl-benzimidazol-2-one, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahyrothiophenyl, 3-tetrahyrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorphblino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 4-thiazolidinyl, diazolonyl, N-substituted diazolonyl, 1-phthalimidyl, 1-3-alkyl-phthalimidyl, beazoxane, benzopyrolidine, benzopiperidine, benzoxolane, benzothiolane, benzothiane,
[0038] Suitable substituents on an aliphatic group, aromatic group (carbocyclic and heteroaryl), non-aromatic heterocyclic ring or benzyl group include, for example, an electron withdrawing group, a halogen, azido, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group), -Q-(substituted aromatic group), -Q-(CH2)p-(substituted or unsubstituted aromatic group) (p is an integer from 1-5), -Q-(non-aromatic heterocyclic group) or -Q-(CH2)p-(non-aromatic heterocyclic group).
[0039] A substituted non-aromatic heterocyclic ring, benzyl group or aromatic group can also have an aliphatic or substituted aliphatic group, as a substituent. A substituted aliphatic group can also have an oxo group, epoxy group, non-aromatic heterocyclic ring, benzyl group, substituted benzyl group, aromatic group or substituted aromatic group as a substituent. A substituted non-aromatic heterocyclic ring can also have =O, =S, =NH or =N(aliphatic, aromatic or substituted aromatic group) as a substituent. A substituted aliphatic, substituted aromatic, substituted non-aromatic heterocyclic ring or substituted benzyl group can have more than one substituent.
[0040] Acyl groups include substituted and unsubstituted aliphatic carbonyl, aromatic carbonyl, aliphatic sulfonyl and aromatic sulfonyl. Suitable electron withdrawing groups include, for example, alkylimines, alkylsulfonyl, carboxamido, carboxylic alkyl esters, -CH=NH, -CN, -NO2 and halogens.
[0041] In the structural formulas depicted herein, the single or double bond by which a chemical group or moiety is connected to the remainder of the molecule or compound is indicated by the following symbol:
For example, the corresponding symbol in Structural Formulas (II) and (III) indicates the double bond by which the central ring of the tricyclic ring system is connected to the remainder of the molecule represented by Structural Formula (I).
[0042] A "subject" is preferably a bird or mammal, such as a human, but can also be an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs,' cats, and the like), farm animals (e.g., cows, sheep, fowl, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
[0043] An "effective amount" of a compound is an amount which results in the inhibition of one or more processes mediated by the binding of a chemokine to a receptor in a subject with a disease associated with aberrant leukocyte recruitment and/or activation. Examples of such processes include leukocyte migration, integrin activation, transient increases in the concentration of intracellular free calcium [Ca2+]i and granule release of proinflammatory mediators. Alternatively, an "effective amount" of a compound.is a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in the prevention of or a decrease in the symptoms associated with a disease associated with aberrant leukocyte recruitment and/or activation.
[0044] The amount of compound administered to the individual will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
[0045] Typically, an effective amount of the compound can range from about 0.1 mg per day to about 100 mg per day for an adult. Preferably, the dosage ranges from about 1 mg per day to about 100 mg per day. An antagonist of chemokine receptor function can also be administered in combination with one or more additional therapeutic agents, e.g. theophylline, β-adrenergic bronchodilators, corticosteroids, antihistamines, antiallergic agents, immunosuppressive agents (e.g., cyclosporin A, FK-506, prednisone, methylprednisolone) and the like.
[0046] The compound can be administered by any suitable route, including, for example, orally in capsules, suspensions or tablets or by parenteral administration. Pareriteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection. The compound can also be administered orally (e.g., dietary), transdermally, topically, by inhalation (e.g., intrabronchial, intranasal, oral inhalation or intranasal drops), or rectally, depending on the disease or condition to be treated. Oral or parenteral administration are preferred modes of administration.
[0047] The compound can be administered to the individual in conjunction with an acceptable pharmaceutical or physiological carrier as part of a pharmaceutical composition for treatment of HIV infection, inflammatory disease, or the other diseases discussed above.
[0048] Formulation of a compound to be administered will vary according to the route of administration selected (e.g., solution, emulsion, capsule). Suitable carriers may contain inert ingredients which do not interact with the compound. Standard pharmaceutical formulation techniques can be employed, such as those described in Remington's Pharmaceutical Sciences, Mack Publishirig Company, Easton, PA. Suitable carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about 0.9% benzyl alcohol), phosphate-buffered saline, Hank's solution, Ringer's-lactate and the like. Methods for encapsulating compositions (such as in a coating of hard gelatin or cyclodextran) are known in the art (Baker, et al., "Controlled Release of Biological Active Agents", John Wiley and Sons, 1986).
[0049] The activity of compounds of the present invention can be assessed using suitable assays, such as receptor binding assays and chemotaxis assays. For example, as described in the Exemplification Section, small molecule antagonists of RANTES and MIP-1α binding have been identified utilizing THP-1 cells which bind RANTES and chemotax in response to RANTES and MIP-1α as a model for leukocyte chemotaxis. Specifically, a high through-put receptor binding assay, which monitors 125I-RANTES and 125I-MIP-1α binding to THP-1 cell membranes, was used to identify small molecule antagonists which block binding of RANTES and MIP-1α.
[0050] Compounds of the present invention can also be identified by virtue of their ability to inhibit the activation steps triggered by binding of a chemokine to its receptor, such as chemotaxis, integrin activation and granule mediator release. They can also be identified by virtue of their ability to block RANTES and MIP-1α mediated HL-60, T-cell, peripheral blood mononuclear cell, and eosinophil chemotactic response.
[0051] The compounds disclosed herein can be prepared according to schemes differing slightly from those shown in Figures 1 to 5 and 7. The schemes are described in greater detail below.
[0053] Rings A and B are both phenyl rings (which are outside the scope of the invention), analogous compounds with a pyridyl group for Ring A and a phenyl group for Ring B (compounds according to the invention) can be prepared by using starting materials with a nitrogen atom in the appropriate the position in Ring A. These starting materials can be prepared according to methods disclosed in JP 61/152673, U.S. Patent 5089496, WO 89/10369, WO 92/20681 and WO 93/02081.
[0054] Figure 1 shows the preparation of compounds represented by Structural Formula (i). This differs from Structural Formula (I) in that Ring A lacks a nitrogen atom (i.e. Ring A is phenyl, rather than pyridyl). L1 is PPh3Cl, PPh3Br, PPh3I or (EtO)2P(O), L2 is a suitable leaving group such as halogen, p-toluene sulfonate, mesylate, alkoxy, and phenoxy; Pg is a suitable protecting group such as tetrahydropyranyl; and the other symbols are as defined above.
[0055] In Step 1 of Figure 1, a Wittig reaction is carried out in a solvent such as ether, or tetrahydrofuran (THF) in the presence of a base such as sodium hydride, n-butyl lithium or lithium diisopropylamide (LDA) at 0°C up to the reflux temperature for the solvent used for 5 minutes to 72 h. Compounds represented by Formula ii in Figure 1 can be prepared by methods disclosed in JP 61/152673, U.S. Patent 5089496, WO 89/10369, WO 92/20681 and WO 93/02081.
[0056] In Step 2 of Figure 1, deprotection is carried out with an acid in a solvent such as methanol at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h. Alternatively, a compound of represented by Formula v in Figure 1 can be prepared directly from step 1 without isolating an intermediate.
[0057] The reaction mixture obtained after the work up of the reaction described in step 1 can be dissolved in the solvent and reacted with the acid. In Step 3 of Figure 1, the hydroxy group can be converted to a leaving group by known methods. Compounds represented by Formula vi in Figure 1 can be prepared by methods disclosed in J. Med. Chem., 1992 (35) 2074-2084 and JP 61/152673.
[0058] In Step 4 of Figure 1, an alkylation reaction is carried out in a solvent such as acetone, methyl ethyl ketone, ethyl acetate, toluene, tetrahydrofuran (THF) or dimethylformamide (DMF) in the presence of a base such as potassium carbonate or sodium hydride and a catalyst such as an alkali metal iodide at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.
[0059] Figure 2 shows the preparation of compounds represented by Compound (vi-b). In Step 1 of Figure 2, a Grignard reaction may be carried out in a solvent such as ether, or tetrahydrofuran (THF) at 0°C up to the reflux temperature for the solvent used for 5 minuets to 72 h. Compound vii is available commercially.
[0060] In Step 2 of Figure 2, bromination may be carried out with brominate agents such as hydrobromic acid, bromotrimethylsilane or boron tribromide-methyl sulfide complex in a solvent such as acetic acid, dichloromethane or dichloroethane at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.
[0061] Figure 3 shows the preparation of compounds represented by Structural Formula, (i). In Figure 3, a reductive amination may be carried out with reducing regents such as sodium cyanoborohydride, sodium acetoxyborohydride or sodium borohydride in a solvent such as methanol, ethanol, tetrahydrofuran (THF), dichloromethane or dichloroethane at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.
[0062] Figure 4 shows the preparation of compounds represented by Structural Formula (i), where in Z is represented by Structural Formula:
wherein Ring A and/or Ring B in Z is substituted with R40. In Figure 4, the alkylation reaction can be carried out in a solvent such as acetone, methyl ethyl ketone, ethyl acetate, toluene; tetrahydrofuran (THF) or dimethylformamide (DMF) in the presence of a base such as potassium carbonate or sodium hydride and a catalyst such as an alkali metal iodide at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.
[0063] Figure 5 is a schematic showing the preparation of the compounds represented by Structural Formula (i), wherein Z is represented by Structural Formula (X) above and wherein Ring A and/or Ring B in Z is substituted with -(O)u-(CH2)t-COOR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20. In Figure 5, the hydrolysis reaction may be carried out in a mixture of aqueous alkali metal hydroxide solution and a solvent such as methanol, ethanol, tetrahydrofuran (THF) or dioxan at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h. The acylation reaction can be carried out using dicyclohexylcarbodiimide (DCC) or (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (DEC) in a solvent such as tetrahydrofuran (THF), dimethylformamide (DMF) or methylene chloride in the presence of a base such as pyridine or triethylamine (when necessary) at temperatures of 0 to 100°C for 5 minutes to 72 h.
[0064] Figure 7 shows the preparation of compounds represented by Structural Formula (i), wherein Z is represented by Structural Formula (X) and wherein Ring A or Ring B in Z is substituted with R40. L4 is a suitable leaving group such as halogen or trifluoromethylsulfonate.
[0065] In Figure 7, a palladium coupling reaction such as Stille coupling, Suzuki coupling, Heck reaction, or carboxylation using carbon monoxide may be carried out using a palladium catalyst such as tetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladium chloride, and palladium acetate in a solvent such as tetrahydrofuran (THF), 1,4-dioxane, toluene, dimethylformamide (DMF), or dimethylsufoxide (DMSO) in the presence of additive (when necessary) such as triphenylphosphine, 1,1'-bis(diphenylphosphino)ferrocene, triethylamine, sodium bicarbonate, tetraethylammonium chloride, or lithium chloride at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.
[0066] Compounds according to the invention, represented by Structural Formula (I), wherein Z is represented by Structural Formulas (II) or (III), X is -CO-NRc- and Rc is -(CH2)s-COOR30, -(CH2)s-C(O) -NR31R32 or -(CH2)s-NHC(O)-O-R30, can be prepared by suitable modification of the scheme shown in Figure 1-5 and 7. One modification utilizes the starting material shown in Figure 1, wherein X is -CO-NH-. The amide is then alkylated with L3-(CH2)s-COOR30, wherein L3 is a suitable leaving group, using the alkylation procedures described above. The remainder of the synthesis is as described in Figures 1 - 5 and 7.
[0067] The invention is illustrated by the following examples which are not intended to be limiting in any way.
Example 1 - Membrane Preparations for Chemokine Binding and Binding Assays
[0068] Membranes were prepared from THP-1 cells (ATCC #TIB202). Cells were harvested by centrifugation, washed twice with PBS (phosphate-buffered saline)., and the cell pellets were frozen at -70 to -85°C. The frozen pellet was thawed in ice-cold lysis buffer consisting of 5 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane-sulfonic acid) pH 7.5, 2 mM EDTA (ethylenediaminetetraacetic acid), 5 µg/ml each aprotinin, leupeptin, and chymostatin (protease inhibitors), and 100 µg/ml PMSF (phenyl methane sulfonyl fluoride - also a protease inhibitor), at a concentration of 1 to 5 x 107 cells/ml. This procedure results in cell lysis. The suspension was mixed well to resuspend all of the frozen cell pellet. Nuclei and cell debris were removed by centrifugation of 400 x g for 10 minutes at 4°C. The supernatant was transferred to a fresh tube and the membrane fragments were collected by centrifugation at 25,000 x g for 30 minutes at 4°C. The supernatant was aspirated and the pellet was resuspended in freezing buffer consisting of 10 mM HEPES pH 7.5, 300 mM sucrose, 1 µg/ml each aprotinin, leupeptin, and chymostatin, and 10 µg/ml PMSF (approximately 0.1 ml per each 108 cells). All clumps were resolved using a minihomogenizer, and the total protein concentration was determined using a protein assay kit (Bio-Rad, Hercules, CA, cat #500-0002). The membrane solution was then aliquoted and frozen at -70 to -85°C until needed.
[0069] Binding Assays utilized the.membranes described above. Membrane protein (2 to 20 µg total membrane protein) was incubated with 0.1 to 0.2 nM 125I-labeled RANTES or MIP-1α with or without unlabeled competitor (RANTES or MIP-1α) or various concentrations of compounds. The binding reactions were performed in 60 to 100 µl of a binding buffer consisting of 10 mM HEPES pH 7.2, 1 mM CaCl2, 5 mM MgCl2, and 0.5% BSA (bovine serum albumin), for 60 min at room temperature. The binding reactions were terminated by harvesting the membranes by rapid filtration through glass fiber filters (GF/B or GF/C, Packard) which were presoaked in 0.3% polyethyleneimine. The filters were rinsed with approximately 600 µl of binding buffer containing 0.5 M NaCl, dried, and the amount of bound radioactivity was determined by scintillation counting in a Topcount beta-plate counter.
[0070] The activities of test compounds are reported in the Table below as IC50 values or the inhibitor concentration required for 50% inhibition of specific binding in receptor binding assays using 125I-RANTES or 125I-MIP-1α as ligand and THP-1 cell membranes. Specific binding is defined as the total binding minus the non-specific binding; non-specific binding is the amount of cpm still detected in the presence of excess unlabeled Rantes or MIP-1α.
| BIOLOGICAL DATA | |
| Example | IC50 (µM) |
| Reference Example 1 | <1 |
| Reference Example 2 | <1 |
| 2 | <1 |
| 3 | <1 |
| 4 | <1 |
| 5 | <1 |
| 6 | <1 |
| 7 | <1 |
| 10 | <1 |
| 11 | <1 |
| 12 | <1 |
| 13 | <1 |
| 14 | <1 |
| 15 | <10 |
| 17 | <1 |
| 18 | <1 |
| 19 | <10 |
| 20 | <10 |
| 21 | <10 |
| 22 | <1 |
| 23 | <1 |
| 24 | <1000 |
| 25 | <1 |
| 26 | <10 |
| 27 | <1 |
| 29 | <10 |
| 30 | <10 |
| 31 | <1 |
| 32 | <1 |
| 33 | <1 |
| 37 | <1000 |
| 39 | <1 |
| 40 | >10 |
| 42 | <1 |
| 43 | <1 |
| 61 | <1 |
| 64 | <1 |
| 67 | <1 |
| 68 | <1 |
| 78 | <1 |
| 80 | <1 |
| 81 | <1 |
| 82 | <1 |
| 83 | <1 |
| 84 | <1 |
| 85 | <1 |
| 88 | <1 |
| 89 | <1 |
| 90 | >10 |
| 91 | <1 |
| 92 | <10 |
| 93 | <1 |
| 94 | <1 |
| 95 | <10 |
| 96 | >10 |
| 97 | <10 |
| 98 | <10 |
| 99 | <1000 |
| 100 | <10 |
| 101 | <1 |
| 102 | <1 |
| 103 | <1 |
| 104 | <1 |
| 105 | <1 |
| 108 | <1 |
| 109 | <1 |
| 110 | <1 |
| 111 | <10 |
| 112 | <1 |
| 113 | <1 |
| 114 | <10 |
| 121 | <1 |
| 122 | <1 |
| 123 | <1 |
| 124 | <1 |
| 126 | <1 |
| 129 | <1 |
| 130 | <1 |
| 131 | <1 |
| 132 | <10 |
| 133 | <1000 |
| 134 | <1 |
| 135 | <1 |
| 136 | >10 |
| 138 | <1 |
| 139 | <1 |
| 140 | <10 |
| 142 | <1 |
| 144 | <1 |
| 193 | <10 |
Reference Example 1 -4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-ethoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol
[0071] To a solution of 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-hydroxydibenz[b,eloxepin-11-ylidene)propyl]piperidin-4-ol (Example 32) (200mg) in DMF (5ml) were added sodium hydride (60% in oil, 25mg), ethyl iodide (0.052ml) and the mixture was stirred at room temperature for 1 hour. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (170mg).
1H-NMR (CDCl3) δ: 1.37(3H,t), 1.60-1.65(2H,m), 1.95-2.08(3H,m), 2.28-75(8H,m), 3.96(2H,q), 5.15(2H,brs), 6.02(1H,t), 6.68(2H,brs), 6.82(1H,brs), 7.19-7.42(8H,m).
MS m/z: 490(M+1)
Reference Example 2 -4-(4-Chlorophenyl)-1-[3-(6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]-4-methoxypiperidine
[0072] To a solution of 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol (Example 2)(404mg) in DMF (5ml) were added sodium hydride (60% in oil, 50mg), methyl iodide (0.07ml) and the mixture was stirred at room temperature for 1 hour. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (100mg).
1H-NMR (CDCl3) δ: 1.90-2.04 (4H,m), 2.34-2.62(8H,m), 2.93(3H,s), 5.25(2H,brs), 6.04(1H,t), 6.75-6.91(3H,m), 7.09-7.37(9H,m).
MS m/z: 460 (M+1)
Example 2 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
Step 1
[0073] To a solution of the product of example 3, step 1 (4.3g) in dichloroethane (100ml) was added boron tribromide-methyl sulfide complex (19.3g) and the mixture was heated to reflux for 3 hour. Water and ethyl acetate were added to the reaction mixture and neutralized with dilute NaOH solution. The organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:2) to give 5-(3-bromopropylidene)-5,11-dihydro-7-hydroxy [1]benzoxepino[2,3-b]pyridine (3.2g).
1H-NMR (CDCl3) δ: 2.72(2H,q), 3.45(2H,t), 5.28(2H,brs), 6.03(1H,t), 6.66-6.80(3H,m), 7.26(1H,dd), 7.58(1H,dd), 8.51(1H,dd).
Step 2
[0074] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 5-(3-bromopropylidene)-5,11-dihydro-7-methoxy [1]benzoxepino[2,3-b]pyridine with the product of step 1.
1H-NMR (DMSO-d6) δ: 1.46-1.51(2H,m), 1.74-1.85(2H,m), 2.29-2.51(8H,m), 5.15(2H,brs), 6.07(1H,t), 6.61-6.70(3H,m), 7.33-7.48(5H,m), 7.73(1H,dd), 8.47(1H,dd), 9.06(1H,s).
MS m/z: 463(M+1)
Example 3 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
Step 1
[0075] To a solution of 5,11-dihydro-7-methoxy [1]benzoxepino[2,3-b]pyridin-5-one (5.0g) in THF (50ml) was added 1.1M cyclopropylmagnesium bromide THF solution (25ml) at 0°C. The reaction mixture was warmed to room temperature, and stirred for 30 minutes. Aqueous ammonium chloride and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was filtered and washed with ethyl acetate-hexane (1:2) to give 5-cyclopropyl-5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ol (5.0g).
Step 2
[0076] To a solution of the product of step 1 (4.3g) in acetic acid (30ml) was added 48% aqueous HBr (25ml) at 10°C. The reaction mixture was warmed to room temperature, and stirred for 12 hours. Water and ethyl acetate were added to the reaction mixture and neutralized with dilute NaOH solution. The organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:4) to give 5-(3-bromopropylidene)-5,11-dihydro-7-methoxy [1]benzoxepino[2,3-b]pyridine (5.6g).
1H-NMR (CDCl3) δ: 2.74(2H,q), 3.46(2H,t), 3.78(3H,s), 5.25(2H,brs), 6.07(1H,t), 6.72-6.82(3H,m), 7.21-7.42(5H,m), 7.56(1H,dd), 8.45(1H,dd).
Step 3
[0077] To a solution the product of step 2 (1.1g) in DMF (15ml) were added 4-(4-chlorophenyl)-4-hydroxypiperidine (0.81g) and potassium carbonate (0.53g) and the mixture was stirred at room temperature for 3 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with methylene chloride-methanol (10:1) to give the titled compound as major regioisomer (0.86g) and minor one (0.05g).
Major isomer
1H-NMR (CDCl3) δ: 1.64-1.69(2H,m), 1.91-2.08(3H,m), 2.34-2.69(8H,m), 3.77(3H,s), 5.25(2H,brs), 6.07(1H,t), 6.72-6.82(3H,m), 7.21-7.42(5H,m), 7.56(1H,dd), 8.45(1H,dd). MS m/z: 477(M+1)
Minor isomer
1H-NMR (CDCl3) δ: 1.65-1.79(3H,m), 2.01-2.13(2H,m), 2.35-2.76(8H,m), 3.76(3H,s), 5.22(2H,brs), 5.95(1H,t), 6.72-6.80(2H,m), 7.06(1H,d), 7.16(1H,dd), 7.28(2H,d), 7.42(2H,d), 7.66(1H,dd), 8.39(1H,dd).
MS m/z: 477(M+1)
Example 4 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxy [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0078] The titled compound was prepared by following the procedure of reference example 1, but replacing 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-hydroxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol with 4-(4-chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol (example 44).
1H-NMR (CDCl3) δ: 1.38(3H,t), 1.67-1.72(3H,m), 2.05-2.16(2H,m), 2.40-2.80(8H,m), 3.99(2H,q), 5.26(2H,brs), 6.05(1H,t), 6.71-6.82(3H,m), 7.23-7.43(5H,m), 7.57(1H,dd), 8.47 (1H,dd).
MS m/z: 491(M+1)
Example 5 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-isopropoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0079] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with isopropyl bromide.
1H-NMR (CDCl3) δ: 1.30(6H,d), 1.60-1.70(3H,m), 1.99-2.09(2H,m), 2.33-2.69(8H,m), 4.37-4.48(1H,m), 5.26(2H,brs), 6.06(1H,t), 6.73-6.82(3H,m), 7.21-7.43(5H,m), 7.55(1H,dd), 8.47(1H,dd).
MS m/z: 505(M+1)
Example 6 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxycarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0080] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with ethyl bromoacetate.
1H-NMR (CDCl3) δ: 1.28(3H,t), 1.63-1.63(2H,m), 1.97-2.02(3H,m), 2.33-2.68(8H,m), 4.24(2H,q), 4.55(2H,s), 5.26(2H,brs), 6.06(1H,t), 6.73-6.88(3H,m), 7.21-7.42(5H,m), 7.55(1H,dd), 8.44(1H,dd).
MS m/z: 549(M+1)
Example 7 -4-(4-Chlorophenyl)-1-[3-(7-cyanomethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0081] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with bromoacetonitrile.
1H-NMR (CDCl3) d: 1.62-1.67(2H,m), 1.94-2.06(2H,m), 2.21(1H,brs), 2.34-2.66(8H,m), 4.70(2H,s), 5.26(2H,brs), 6.10(1H,t), 6.80(2H,brs), 6.92(1H,brs), 7.22-7.41(5H,m), 7.56(1H,dd), 8.44(1H,dd).
MS m/z: 502(M+1)
Example 8 -1-[3-(7-(2-Acetoxyethyl)oxy-5,11-dihydro [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0082] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with 2-bromoethyl acetate.
1H-NMR (CDCl3) δ: 1.65-1.72(3H,m), 1.97-2.09(5H,m), 2.37-2.70(8H,m), 4.11-4.14(2H,m), 4.37-4.41(2H,m), 5.25(2H,brs), 6.07(1H,t), 6.75-6.84(3H,m), 7.23-7.43(5H,m), 7.56(1H,dd), 8.47(1H,dd).
MS m/z: 549(M+1)
Example 9 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-hydroxyethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0083] To a solution of 1-[3-(7-(2-acetoxyethyl)oxy-5,11-dihydro [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol (Example 8) (140mg) in ethanol (5ml) were added 15% sodiun hydroxide aqueous solution (2ml) and the mixture was heated to reflux for 1 hour.
[0084] Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate.
[0085] The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with methylene chloride-methanol (10:1) to give the titled compound (120mg).
1H-NMR (CDCl3) δ: 1.64-1.69(2H,m), 1.98-2.10(3H,m), 2.36-2.79(8H,m), 3.89-3.94(2H,m), 3.99-4.04(2H,m), 5.24(2H,brs), 6.04(1H,t), 6.71-6.84(3H,m), 7.23-7.41(5H,m), 7.54(1H,dd), 8.43 (1H,dd).
MS m/z: 507(M+1)
Example 10 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-morpholinoethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0086] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with 4-(2-chloroethyl)morpholine hydrochloride.
1H-NMR (CDCl3) δ: 1.62-1.67(2H,m), 1.95-2.08(2H,m), 2.20-2.67(13H,m), 2.74(2H,t), 3.67-3.71(4H,m), 4.04(2H,t), 5.23(2H,brs), 6.05(1H,t), 6.73-6.82(3H,m), 7.20-7.41(5H,m), 7.53(1H,dd), 8.42(1H,dd).
MS m/z: 576(M+1)
Example 11 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
Step 1
[0087] 5-(3-Bromopropylidene)-5,11-dihydro [1]benzoxepino[2,3-b]pyridine was prepared by following the procedure of example 3, step 1 and 2, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDCl3) δ: 2.71(2H,q), 3.46(2H,t), 5.33(2H,brs), 6.04(1H,t), 7.01-7.17(3H,m), 7.29(1H,dd), 7.56(1H,dd), 8.53(1H,dd).
Step 2
[0088] The titled compound was prepared by following the procedure of example 45, step 3, but replacing 5-(3-bromopropylidene)-5,11-dihydro-7-methoxy [1]benzoxepino[2,3-b]pyridine with the product of step 1.
1H-NMR (CDCl3) δ: 1.66-1.71(2H,m), 2.00-2.20(3H,m), 2.36-2.69(8H,m), 5.34(2H,brs), 6.10(1H,t), 6.83-6.96(3H,m), 7.17-7.44(6H,m), 7.60(1H,dd), 8.46(1H,dd).
MS m/z: 447(M+1)
Example 12 -1-[3-(8-Bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
Step 1
[0089] 8-Bromo-5-(3-bromopropylidene)-5,11-dihydro[1]benzoxepino[2,3-b]pyridine was prepared by following the procedure of example 3, step 1 and 2, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 8-bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDCl3) δ: 2.75(2H,q), 3.50(2H,t), 5.38(2H,brs), 6.08(1H,t), 6.85-6.98(2H,m), 7.18-7.35(3H,m), 7.59(1H,dd), 8.54(1H,dd).
Step 2
[0090] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 5-(3-bromopropylidene)-5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridine with the product of step 1.
1H-NMR (CDCl3) δ: 1.64-1.69(2H,m), 1.90-2.07(3H,m), 2.30-2.67(8H,m), 5.30(2H,brs), 6.08(1H,t), 7.00-7.07(2H,m), 7.13(1H,d), 7.25-7.42(5H,m), 7.56(1H,dd), 8.47(1H,dd).
MS m/z: 525, 527(M+1)
Example 13 -4-(4-Chlorophenyl)-1-[3-(10,11-dihydro-10-oxo-5H-pyrido[2,3-c][2]benzazepin-5-ylidene)propyl]piperidin-4-ol
Step 1
[0091] 5-(3-Bromopropylidene)-10,11-dihydro-10-oxo-5H-pyrido[2,3-c][2]benzazepine was prepared by following the procedure of example 3, step 1 and 2, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 10,11-dihydro-5H-pyrido[2,3-c][2]benzazepin-5,10-dione.
1H-NMR (CDCl3) δ: 2.75-2.90(2H,m), 3.45 (2H,t), 5.92(1H,t), 7.04-7.70(5H,m), 8.10(1H,dd), 8.48(1H,dd), 10.00(1H,brs).
Step 2
[0092] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 5- (3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with the product of step 1.
1H-NMR (CDCl3) δ: 1.64-1.69(3H,m), 2.00-2.12(2H,m), 2.35-2.70(8H,m), 5.82(1H,t), 7.08(1H,dd), 7.23-7.62(8H,m), 8.04(1H,dd), 8.32(1H,dd), 8.76(1H,brs).
MS m/z: 460(M+1)
Example 14 -4-(4-Chlorophenyl)-1-[3-(10,11-dihydro-11-methyl-10-oxo-5H-pyrido[2,3-c][2]benzazepin-5-ylidene)propyl]piperidin-4-ol
[0093] The titled compound was prepared by following the procedure of reference example 2, but replacing of 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol with 5-(3-bromopropylidene)-10,11-dihydro-10-oxo-5H-pyrido[2,3-c][2]benzazepine.
1H-NMR (CDCl3) δ: 1.64-1.70 (3H,m), 2.00-2.10(2H,m), 2.41-2.69(8H,m), 3.62(3H.s), 5.82(1H,t), 7.07(1H,dd), 7.25-7.54(8H,m), 7.91(1H,dd), 8.34(1H,dd).
MS m/z: 474(M+1)
Example 15 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)ethyl]piperidin-4-ol
Step 1
[0094] To a solution of methyltriphenylphosphonium bromide (2.2g) in THF (20ml) was added 1.6M n-butyl lithium hexane solution (2.9ml) at 0°C for 30 minutes. To the reaction mixture cooled to 0°C was added 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one (1.0g) dropwise as THF solution (5ml), and the mixture was warmed to room temperature, and stirred for 3 hours. Aqueous ammonium chloride and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluding with ethyl acetate-hexane (1:4) to give 5,11-dihydro-7-methoxy-5-methylenepyrido[2,3-c][1]benzoxepine (0.14g).
Step 2
[0095] To a solution of DMF (0.54ml) was added phosphorus oxychloride (0.41ml) at 0°C for 10 minutes. To the reaction mixture was added the product of step 1 (210mg) in carbontetrachloride (5ml) and the mixture was heated to reflux for 5 hours. Aqueous sodium bicarbonate and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:4) to give 3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)acetaldehyde (130mg).
1H-NMR (CDCl3) δ: 3.77(0.7x3H,s),3.79(0.3x3H, s), 5.31(2H,s), 6.46(0.7x1H,d), 6.52(0.3x1H,d), 6.78-7.40(4H,m), 7.68(0.3x1H,dd), 7.78(0.7x1H,dd), 8.55(0.7x1H,dd), 8.64(0.3x1H,dd), 9.62(0.3x1H,d), 9.79(0.7x1H,d).
Step 3
[0096] The titled compound was prepared by following the procedure of example 16, step 2, but replacing of 3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propanaldehyde with product of step 2.
1H-NMR (CDCl3) δ: 1.64-1.82(2H,m), 1.92-2.22(3H,m), 2.43-2.58(2H,m), 2.79-3.45(6H,m), 3.68(0.3x3H,s), 3.70(0.7x3H,s), 5.24(2H,brs), 6.18(0.7x1H,t), 6.21(0.3x1H,t), 6.72-7.42(8H,m), 7.78(0.3x1H,dd), 7.85(0.7x1H,dd), 8.42(0.7x1H,dd), 8.46(0.3x1H,dd).
MS m/z: 463(M+1).
Example 16 -4-(4-Chlorophenyl)-1-[4-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)butyl]piperidin-4-ol
Step 1
[0097] 3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propenaldehyde was prepared by following the procedure of example 15, step 2, but replacing 5,11-dihydro-7-methoxy-5-methylene[1]benzoxepino[2,3-b]pyridine with 5,11-dihydro-7-methoxy-5-(propyl-1-ene) [1]benzoxepino[2,3-b]pyridine (by-product of example 3, step 3).
1H-NMR (CDCl3) δ: 3.78(0.3x3H,s), 3.80(0.7x3H,s), 5.32(2H,brs), 6.34-6.39(1H,m), 6.72-7.38 (6H,m), 7.58(0.7x1H,dd), 7.77(0.3x1H,dd), 8.49(0.3x1H,dd), 8.60(0.7x1H,dd), 9.51(0.7x1H,d), 9.54(0.3x1H,d).
Step 2
[0098] To a solution of the product of step 1 (90mg) in dichloromethane (6ml) were added sodium triacetoxyborohydride (170mg), 4-(4-chlorophenyl)-4-hydroxypiperidine (70mg) and acetic acid (0.02ml) and the mixture stirred at room temperature for 24 hour. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with dichloromethane-methanol (95:5) to give 4-(4-chlorophenyl)-1-[4-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)buten-2-yl]piperidin-4-ol (110mg).
1H-NMR (CDCl3) δ: 1.68-1.73(2H,m), 2.04-2.16(2H,m), 2.43-2.72(3H,m), 2.77-2.81(2H,m), 3.08-3.13(2H,m), 3.73(0.3x3H,s), 3.77(0.7x3H,s), 5.20(2H,brs), 5.98-6.05(1H,m), 6.23-7.43(10H,m), 7.58(0.7x1H,dd), 7.65(0.3x1H,dd), 8.37(0.3x1H,dd), 8.45(0.7x1H,dd).
MS m/z: 489(M+1).
Step 3
[0099] To a solution of the product of step 2 (8mg) in ethanol (2ml) were added 10% Pd-C (2mg) was stirred under hydrogen (under a balloon) at room temperature for 1 hour. The mixture was filtered through the celite and distilled off under reduced pressure to give the titled compound (6mg).
1H-NMR (CDCl3) δ: 1.68-3.00(15H,m), 3.77(3H,s), 5.18-5.35(2H,m), 5.94(0.4H,t, E isomer), 6.06(0.6H,t, Z isomer), 6.65-6.88(3H,m), 7.05-7.73(6H,m), 8.30-8.56(1H,m).
MS m/z: 491(M+1)
Example 17 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-phenyl-4-ol
[0100] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-phenyl-4-hydroxypiperidine.
1H-NMR (CDCl3) d: 1.68-1.73(2H,m), 2.02-2.15(3H,m), 2.38-2.72(8H,m), 3.77(3H,s), 5.26(2H,brs), 6.08(1H,t), 6.72-6.83(3H,m), 7.21-7.36(4H,m), 7.46-7.49(2H,m), 7.58(1H,dd), 8.46(1H,dd)
MS m/z: 443 (M+1).
Example 18 -4-(4-Bromophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0101] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-bromophenyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.65-1.69(2H,m), 2.00-2.10(3H,m), 2.37-2.71(8H,m), 3.76(3H,s), 5.24(2H,brs), 6.05(1H,t), 6.70-6.82(3H,m), 7.24(1H,dd), 7.38 (2H,d), 7.44(2H,s), 7.52(1H,dd), 8.44(1H,dd).
MS m/z: 521,523 (M+1).
Example 19 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0102] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.43-1.60(2H,m), 1.80-1.98 (2H,m), 2.00-2.18(3H,m), 2.34-2.48 (4H,m), 2.63-2.76(2H,m), 3.64-3.73(1H,m), 3.70(3H,s), 5.35(2H,brs), 6.06(1H,t), 6.74-6.84(3H,m), 7.25(1H,dd), 7.60(1H,dd), 8.50(1H,dd).
MS m/z: 367 (M+1).
Example 20 -4-Benzyl-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0103] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-benzyl-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.42-1.57(3H,m), 1.62-1.75(2H,m), 2.22-2.70(8H,m), 2.79(2H,s), 3.80(3H,s), 5.25(2H,brs), 6.08(1H,t), 6.73-6.84(3H,m), 7.18-7.24(6H,m), 7.57(1H,dd), 8.50(1H,dd).
MS m/z: 457 (M+1).
Example 21 -4-Cyano-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-phenylpiperidine
[0104] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-cyano-4-phenylpiperidine.
1H-NMR (CDCl3) δ: 1.97-2.06(4H,m), 2.37-2.60(6H,m), 2.85-2.90(2H,m), 3.79(3H,s), 5.27(2H,brs), 6.08(1H,t), 6.72-6.84(3H,m), 7.24-7.58(7H,m), 8.49(1H,dd).
MS m/z: 452 (M+1).
Example 22 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-phenylpiperidine
[0105] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-phenylpiperidine.
1H-NMR (CDCl3) δ: 1.73-1.79(4H,m), 1.96-2.03(2H,m), 2.37-2.52(5H,m), 2.86-2.94(2H,m), 3.77(3H,s), 5.26(2H,brs). 6.08(1H,t), 6.72-6.83(3H,m), 7.17-7.31(6H,m), 7.56 (1H,dd), 8.49(1H,dd).
MS m/z 426 (M+1).
Example 23 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0106] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-chlorophenyl)piperidine.
1H-NMR (CDCl3) δ: 1.68-1.74(4H,m), 1.96-2.03(2H,m), 2.36-2.48(5H,m),2.89-2.94(2H,m), 3.77(3H,s), 5.27(2H,brs), 6.07(1H,t), 6.73-6.83(3H,m), 7.10-7.27(5H,m), 7.57(1H,dd), 8.48(1H,dd).
MS m/z: 461 (M+1).
Example 24 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-piperidinopiperidine
[0107] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-piperidinopiperidine.
1H-NMR (CDCl3) δ: 1.40-2.00(12H,m), 2.15-2.60(9H,m), 2.80-2.92(2H,m), 3.80(3H,s), 5.28(2H,brs), 6.05(1H,t), 6.75-6.86(3H,m), 7.30(1H,dd), 7.55(1H,dd), 8.46(1H,dd).
MS m/z 434 (M+1).
Example 25 -1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2,3-b]pyridin-5-ylidene)propyl]-4-(2-keto-1-benzimidazolinyl)piperidine
[0108] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(2-keto-1-benzimidazolinyl)piperidine.
1H-NMR (CDCl3) δ: 1.75-1.79(2H,m), 2.03-2.15(2H,m), 2.38-2.52(6H,m), 2.93-2.98 (2H,m), 3.78(3H,s), 4.30-4.38(1H,m), 5.30(2H,brs), 6.10(1H,t), 6.73-6.84(3H,m), 7.01-7.03(3H,m), 7.21-7.28(2H,m), 7.59(1H,dd), 8.48(1H,dd).
MS m/z: 483 (M+1).
Example 26 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(2-keto-3-methyl-1-benzimidazolinyl)piperidine
[0109] The titled compound was prepared by following the procedure of reference example 2, but replacing of 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-ol with 1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(2-keto-1-benzimidazolinyl)piperidine.
1H-NMR (CDCl3) δ: 1.72-1.76(2H,m), 2.09-2.14(2H,m), 2.23-2.54(6H,m), 2.91-2.96 (2H,m), 3.38(3H,s), 3.77(3H,s), 4.30-4.37(1H,m), 5.27(2H,brs), 6.08(1H,t), 6.71-6.83(3H,m), 6.93-7.06(3H,m), 7.23-7.60(2H,m), 8.08(1H,dd), 8.48(1H,dd).
MS m/z: 497 (M+1).
Example 27 -8-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one
[0110] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one.
1H-NMR (CDCl3) δ: 1.65-1.70(2H,m), 2.36-2.41(2H,m), 2.53-2.79(8H,m), 3.76(3H, s), 4.70(2H,s), 5.25(2H,brs), 6.10(1H,t), 6.71-6.88(6H,m), 7.21-7.27(3H,m), 7.58-7.61(2H,m), 8.48(1H,dd).
MS m/z: 497 (M+1).
Example 28 -4-Anilino-4-carbamyl-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0111] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-anilino-4-carbamylpiperidine.
1H-NMR (CDCl3) δ: 1.85-1.90(2H,m), 2.03-2.08(2H,m), 2.19-2.46(6H,m), 2.62-2.67(2H,m), 3.75(3H,s), 3.97(1H,brs), 5.27(2H,brs), 5.53-(1H,brs), 6.03(1H,t), 6.60(2H,d), 6.70-6.85(4H,m), 7.12-7.25(4H,m), 7.53(1H,dd), 8.46(1H,dd).
MS m/z 485 (M+1).
Example 29 -4-(3-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0112] The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(3-chlorophenyl)-4-hydroxypiperidine. 1H-NMR (CDCl3) δ: 1.61-1.75(2H,m), 1.98(1H,brs), 1.99(2H,dt), 2.25(3H,s), 2.30-2.76(8H,m), 3.73(3H,s), 5.22(2H,brs), 5.95(0.1H,t, E isomer), 6.04(0.9H,t, Z isomer), 6.71-6.89(3H,m), 6.95(1H,dd), 7.15-7.20(0.3H,m, E isomer),7.21-7.35(2.7H,m, Z isomer), 7.53(0.9H,dd, Z isomer), 7.65(0.1H,dd, E isomer), 8.35(0.1H,dd, E isomer), 8.45(0.9H,dd, Z isomer).
MS m/z: 477(M+1)
Example 30 -4-(2-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0113] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(2-chlorophenyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.98-2.08(2H,m), 2.24(2H,dt), 2.38-2.78(9H,m), 3.77(3H,s), 5.27(2H,brs), 6.08(1H,t), 6.82-6.75(3H,m), 7.28-7.19(3H,m), 7.33(1H,dd), 7.49(1H,dd), 7.58(1H,dd), 8.40(0.1H,dd, Z isomer), 8.47(0.9H,dd, E isomer).
MS m/z: 477(M+1)
Example 31 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-fluorophenyl)piperidin-4-ol
[0114] The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-fluorophenyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.58-1.72(2H,m), 2.04(2H,dt), 2.22-2.78(9H,m), 3.75(3H,s), 5.26(2H,brs), 6.09(1H,t), 6.70-6.88(3H,m), 7.00(2H,dd), 7.23(1H,dd), 7.42(2H,dd), 7.56(1H,dd), 8.41(1H,dd).
MS m/z: 461(M+1)
Example 32 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(p-tolyl)piperidin-4-ol
[0115] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(p-tolyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.65-1.78(2H,m), 2.02(2H,dt), 2.31(3H,s), 2.24-2.75(9H,m), 3.75(3H,s), 5.25(2H,brs), 6.07(1H,t), 6.72-6.84(3H,m), 7.13(2H,d), 7.23(1H,dd), 7.34(1H,d), 7.56(1H,dd), 8.43(1H,dd).
MS m/z: 457(M+1)
Example 33 -4-(3,4-Dichlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino [2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0116] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(3,4-dichlorophenyl)-4-hydroxypiperidine.
1HNMR (CDCl3) δ: 1.58-1.72(2H,m), 1.84(1H,brs), 2.02(2H,td), 2.32-2.72 (8H,m), 3.76(3H,s), 5.27(2H,brs), 5.95(0.1H,t, E isomer), 6.07(0.9H,t, Z isomer), 6.72-6.85 (3H,M), 7.12-7.20(0.2H,m, E isomer), 7.21-7.32(0.18H,m, Z isomer), 7.32-7.45(1H,m), 7.52-7.56(2H,m), 8.37-(0.9H,dd, E siomer), 8.45(0.1H,dd, Z isomer).
MS m/z: 512(M+1)
Example 37 -4-(5-Chloropyridin-2-yl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0117] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(5-chloropyridin-2-yl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.77-1.82 (2H,m), 2.36-2.94(11H,m), 3.77(3H,brs), 5.26(2H,brs), 6.07(1H,t), 6.76-6.84(3H,m), 7.26(1H,dd), 7.57(1H,dd), 8.49-7.48(1H,d), 8.42-8.53(3H,m).
MS m/z: 478(M+1)
Example 39 -4-(5-Chloro-2-keto-1-benzimidazolinyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0118] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(5-chloro-2-keto-1-benzimidazolinyl)piperidine.
1H-NMR (CDCl3) δ: 1.68-1.72(2H,m), 2.03-2.60(8H,m), 2.90-3.02(2H,m), 3.78(3H,s), 4.32-4.21(1H,m), 5.29(2H,brs), 5.95(0.1H,t, E siomer), 6.08(0.9H,t, Z isomer), 6.70-6.92(3H,m), 7.02(1H,dd), 7.08-7.20(1H,m), 7.26(1H,dd), 7.58(0.9H,dd, Z isomer), 7.70(0.1H,dd, E isomer), 8.42(0.1H,dd, E isomer), 8.48(0.9H,dd, Z isomer), 10.5(1H,s). (NH is not observed in the spectrum)
MS m/z: 517(M+1)
Example 40 - 4-(p-Chloroanilino)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0119] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(p-chloroanilino)piperidine.
1H-NMR (CDCl3) δ: 1.20-1.54(2H,m), 1.85-2.20(4H,m), 2.24-2.60(4H,m), 2.73(2H,m), 3.18(1H,m), 3.77(3H,s), 5.27(2H,brs), 6.06(1H,t), 6.47(2H,m), 6.68-6.90(3H,m), 7.07(2H,m), 7.24(1H,dd), 7.57(1H,m), 8.48(1Hdd). NH signal was not observed.
MS m/z: 476(M+1)
Example 42 -1'-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]spiro[isobenzofuran-1(3H),4'-piperidine]
[0120] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with spiro[isobenzofuran-1(3H),4'-piperidine].
1H-NMR (CDCl3) δ: 1.62-1.82(2H,m), 1.92(2H,dt), 2.25-2.85(8H,m), 3.76(3H,s), 5.03(2H,s), 5.30(2H,brs), 6.11(1H,t), 6.68-6.90(3H,m), 7.02-7.34(5H,m), 7.58(1H,dd), 8.48(1H,dd).
MS m/z: 455(M+1)
Example 43 -5-Chloro-1'-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]spiro[isobenzofuran-1(3H),4'-piperidine]
[0121] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 5-chlorospiro[isobenzofuran-1(3H),4'-piperidine].
1H-NMR (CDCl3) δ: 1.69-1.74(2H,m), 1.81-1.93(2H,m), 2.30-2.44(4H,m), 2.52-2.63(2H,m), 2.71-2.75(2H,m), 3.79(3H,s), 5.00(2H,s), 5.28(2H,brs), 6.09(1H,t), 6.73-6.84(3H,m), 7.03(1H,d), 7.17-7.28(3H,m), 7.58(1H,dd), 8.49(1H,dd).
MS m/z: 489(M+1)
Example 61 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro[1]benzothiepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0122] The titled compound was prepared by following the procedure of example 3, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro[1]benzothiepino[2,3-b]pyridin-5-one.
1H-NMR (CDCl3) δ: 1.66-1.78(3H,m), 2.04-2.65(10H,m), 3.66(1H,brd), 5.05(1H,brd), 6.03(1H,t), 7.04-7.46(10H,m), 8.44(1H,dd).
MS m/z: 463(M+1)
Example 64 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-8-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0123] The titled compound was prepared by following the procedure of example 3, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5, 11-dihydro-8-methoxy[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDCl3) δ: 1.66-1.70(3H,m), 1.98-2.09(2H,m), 2.34-2.70(8H,m), 3.75(3H,s), 5.32(2H,brs), 6.02(1H,t), 6.39(1H,d), 6.51(1H,dd), 7.19-7.44(6H,m), 7.57(1H,dd), 8.49(1H,dd).
MS m/z: 477(M+1)
Example 65 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0124] The titled compound was prepared by following the procedure of example 3, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro-7-methyl[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDCl3) δ: 1.50(1H,brs), 1.66-1.70 (2H,m), 1.98-2.10(2H,m), 2.28(3H,s), 2.34-2.42(4H,m), 2.52-2.57(2H,m), 2.66-2.70(2H,m), 5.30(2H,brs), 6.08(1H,t), 6.76(1H,d), 6.97(1H,dd), 7.09(1H,d), 7.24-7.44(5H,m), 7.57 (1H, dd), 8.49(1H,dd).
MS m/z: 461(M+1)
Example 67 -1-[3-(7-Chloro-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0125] The titled compound was prepared by following the procedure of example 3, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 7-chloro-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-one
1H-NMR (CDCl3) δ: 1.66-1.71(3H,m), 2.00-2.10(2H,m), 2.36-2.44(4H,m), 2.52-2.57(2H,m), 2.66-2.70(2H,m), 5.32(2H,brs), 6.13(1H,t), 6.78(1H,d), 7.11(1H,dd), 7.26-7.44(5H,m), 7.58(1H,dd), 8.51(1H,dd).
MS m/z: 481(M+1)
Example 68 -1-[3-(7-Carboxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0126] A mixture of the product of example 117 (500 mg), potassium acetate (330 mg), palladium(II) diacetate (10 mg), 1,1'-bis(diphenylphosphino)ferrocene (93 mg), in dimethylsulfoxide (10 ml) was purged with carbon monoxide for 5 minutes and stirred under a carbon monoxide balloon at 60°C for 3 hours. Water was added to the reaction mixture, the precipitation was filtered. The solid were dissolved with ethyl acetate and dilute sodium hydroxide solution. The aqueous layer was separated and neutralized with dilute hydrochloric acid. The precipitation was filtered to give the titled compound (250 mg).
1H-NMR (DMSO-d6) δ: 1.45-1.55(2H,m), 1.75-1.85(2H,m), 2.36-2.62(8H,m), 5.42(2H,brs), 6.21(1H,t), 6.90(1H,d), 7.40-7.52(5H,m), 7.75(1H,dd), 7.83(1H,dd), 7.95(1H,d), 8.56(1H,dd).
MS m/z: 491(M+1)
Example 78 -4-(4-Chlorophenyl)-1-[3-(5,-11-dihydro-7-propoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0127] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with propyl iodide.
1H-NMR (CDCl3) δ: 1.03(3H,t), 1.65-1.70(2H,m), 1.78(2H,q), 1.98-2.09(3H,m), 2.37-2.45(4H,m), 2.51-2.56(2H,m), 2.66-2.70(2H,m), 3.88(2H,t), 5.26(2H,brs), 6.08(1H,t), 6.72-6.84(3H,m), 7.23-7.43(5H,m), 7.58(1H,dd), 8.43(1H,dd).
MS m/z: 505(M+1)
Example 80 -4-(4-Chlorophenyl)-1-[3-(7-cyclopropylmethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0128] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with cyclopropylmethyl bromide.
1H-NMR (CDCl3) δ: 0.31-0.37(2H,m), 0.60-0.67(2H,m), 1.21-1.28(1H,m), 1.66-1.72(3H,m), 2.01-2.11(2H,m), 2.37-2.71(8H,m), 3.77(2H,d), 5.27(2H,brs), 6.08(1H,t), 6.73-6.86(3H,m), 7.23-7.44(5H,m), 7.58(1H,dd), 8.47(1H,dd).
MS m/z: 517(M+1)
Example 81 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-dimetylaminoethyl) oxy) [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0129] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with 2-(dimethylamino)ethyl chloride hydrochloride.
1H-NMR (CDCl3) δ: 1.71-1.76(2H,m), 2.12-2.21(2H,m), 2.38(6H,s), 2.40-2.79(11H,m), 4.07(2H,t), 5.28(2H,brs), 6.07(1H,t), 6.74-6.86(3H,m), 7.27-7.46(5H,m), 7.59(1H,dd), 8.49(1H,dd).
MS m/z: 534(M+1)
Example 82 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(tetrazol-5-yl)methyloxy) [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
Step 1
[0130] 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-triphenylmethyltetrazol-5-yl)methyloxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol was prepared by following the procedure of example 4, but replacing ethyl iodide with (2-triphenylmethyltetrazol-5-yl)methyl chloride.
1H-NMR (CDCl3) δ: 1.64-1.70(3H,m), 2.02-2.15(2H,m), 2.35-2.71(8H,m),5.29(2H,brs), 5.33(2H,s), 6.03(1H,t), 6.77(1H,d), 6.83(1H,dd), 6.96(1H,d), 7.04-7.08(6H,m), 7.23-7.45(14H,m), 7.54(1H,dd), 8.50(1H,dd).
Step 2
[0131] A solution of the product of step 1 (530 mg) in acetone (2.5 ml), acetic acid (2.5 ml) and water (2.5 ml) was stirred at 55°C for 30 minutes. The reaction mixture was distilled off under reduced pressure. The residue was washed with methanol to give the titled compound (280 mg).
1H-NMR(DMSO-d6) δ: 1.69-1.74(2H,m), 1.99-2.09(2H,m), 2.95-3.14(8H,m), 5.18(2H,brs), 5.20(2H,s), 6.14(1H,t), 6.76(1H,d), 6.93(1H,dd), 7.04(1H,d), 7.39-7.48(5H,m), 7.78(1H,dd), 8.52(1H,dd).
MS m/z: 545(M+1)
Example 83 -1-[3-(7-Carboxymethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0132] To a solution of product of example 6 (3.0 g) in methanol (50 ml) was added 1N sodium hydroxide solution (8 ml) and the mixture stirred at room temperature for 1 hour. The reaction mixture was distilled off under reduced pressure. The residue was dissolved with water and neutralized with 1N hydrochloric acid. The precipitation was filtered and washed with water to give the titled compound (2.6 g).
1H-NMR (DMSO-d6) δ: 1.48-1.53 (2H,m), 1.76-1.88(2H,m), 2.32-2.60(8H,m), 4.60(2H,s), 5.18(2H,brs), 6.16(1H,t), 6.72-6.84(3H,m), 7.34-7.48(5H,m), 7.73(1H,dd), 8.50(1H,dd).
MS m/z: 521(M+1)
Example 84 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-dimethylaminocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0133] To a solution of product of example 83 (420 mg) in dimethylformamide (17 ml) were added 1-hydroxybenzotriazol hydrate (250 mg), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (310 mg), dimethylamine hydrochloride (270 mg) and triethylamine (0.45 ml), and the mixture stirred at room temperature for 12 hours. Water and chloroform were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure to give the titled compound (380 mg).
1H-NMR (CDCl3) δ: 1.67-1.71(2H,m), 1.95-2.11(3H,m), 2.37-2.71(8H,m), 2.97(3H,s), 3.08(3H,s), 4.64-(2H,s), 5.27(2H,brs), 6.09(1H,t), 6.74-6.82(2H,m), 6.93(1H,d), 7.24-7.44(5H,m), 7.58(1H,dd), 8.47(1H,dd).
MS m/z: 548(M+1)
Example 85 -4-(4-Chlorophenyl)-1-(3-(5,11-dihydro-7-morpholinocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0134] The titled compound was prepared by following the procedure of example 84, but replacing dimethylamine hydrochloride with morpholine.
1H-NMR (CDCl3) δ: 1.67-1.71(2H,m), 1.87(1H,brs), 2.00-2.11(2H,m), 2.38-2.71(8H,m), 3.61-3.68(8H,m), 4.65(2H,s), 5.27(2H,brs), 6.09(1H,t), 6.74-6.83(2H,m), 6.90(1H,d), 7.25-7.44(5H,m), 7.58(1H,dd), 8.48(1H,dd).
MS m/z: 590(M+1)
Example 88 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-ethoxycarbonyl-1-methylethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0135] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with ethyl 2-bromoisobutylate.
1H-NMR (CDCl3) δ: 1.27(3H,t), 1.56(6H.s), 1.63-1.71(3H,m), 2.01-2.10(2H,m), 2.35-2.70(8H,m), 4.24(2H,q), 5.28(2H,brs), 6.05(1H,t), 6.67-6.75(2H,m), 6.87(1H,d), 7.24-7.44(5H,m), 7.56(1H,dd), 8.49(1H,dd).
MS m/z: 577(M+1)
Example 89 -1-[3-(7-(1-Carboxy-1-methylethyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0136] The titled compound was prepared by following the procedure of example 83, but replacing product of example 48 with product of example 88.
1H-NMR (DMSO-d6) δ: 1.45-1.52(8H,m), 1.79-1.85(2H,m), 2.28-2.53(8H,m), 5.19(2H,brs), 6.07(1H,t), 6.69-6.73(2H,m), 6.85(1H,d), 7.33-7.47(5H,m), 7.71(1H,dd), 8.48(1H,dd).
MS m/z: 549(M+1)
Example 90 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-methoxyphenyl)piperidin-4-ol
[0137] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-methoxyphenyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.62-1.75(2H,m), 2.08(2H,dt), 2.41-2.76(9H,m), 3.77(3H,s), 3.78(3H,s), 5.26(2H,brs), 6.06(1H,t), 6.75-6.871(5H,m), 7.23(1H,dd), 7.38(2H,d), 7.57(1H,dd), 8.45(1H,dd).
MS m/z: 473 (M+1)
Example 91 -4-(4-Cyanophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0138] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-cyanophenyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.58-1.70(2H,m), 2.03(2H,t), 2.31-2.64(7H,m), 2.65-2.78(2H,m), 3.75(3H,s), 5.26(2H,brs), 5.95(0.1H,t, E isomer), 6.05(0.9H,t, Z isomer), 6.70-6.80(3H,m), 7.22(1H,dd), 7.54-7.68(5H,m), 8.31(0.1H,dd, E iosmer), 8.39(0.9H,dd, Z isomer).
MS m/z:468(M+1)
Example 92 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-hydroxyphenyl)piperidin-4-ol
[0139] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-hydroxyphenyl)-4-hydroxypiperidine.
1HNMR (CDCl3) δ: 1.76-1.88(2H,m), 2.08-2.22(2H,m), 2.45-2.95(9H,m), 3.76(3H,s), 5.28(2H,brs), 5.95(0.3H,t, E isomer), 6.04(0.7H,t, Z iosmer), 6.69-6.72(3H,m), 6.90(2H,d), 7.20-7.30(3H,m), 7.56(0.7H,dd, Z isomer), 7.67(0.3H,dd, E isomer), 8.46(0.7H,dd, Z isomer), 8.47(0.3H,dd, E isomer). OH signal was not observed.
MS m/z: 473 (M+1)
Example 93 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-fluoro-3-methylphenyl)piperidin-4-ol
[0140] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-fluoro-3-methylphenyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.62-1.75(2H,m), 2.05(1H,brs), 2.09(2H,dt), 2.25(3H,s), 2.30-2.76(8H,m), 3.76(3H,s), 5.26(2H, brs), 5.96(0.1H,t, E isomer), 6.07(0.9H,t, Z isomer), 6.75-6.89(3H,m), 6.93(1H,t), 7.11-7.20(0.3H,m, E isomer), 7.21-7.35(0.24H,m, Z isomer), 7.56(0.9H,dd, E isomer), 7.67(0.1H, dd, E isomer), 8.38(0.1H,dd, E isomer), 8.45(0.9H,dd, Z isomer).
MS m/z: 475(M+1)
Example 94 -4-(3,4-difluorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0141] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(3,4-difluorophenyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.58-1.72(2H,m), 1.96(2H,dt), 2.33-2.71(8H,m), 3.73(3H,s), 5.23(2H,brs), 5.94(0.1H,t, E isomer), 6.04(0.9H,t, Z isomer), 8.38-8.36(0.9H,m, Z isomer), 6.68-6.79(3H,m), 6.98-7.38(4H,m), 7.50-7.62(0.9H,m, Z isomer), 7.63-7.68(0.1H,m, E isomer), 8.29-8.32(0.1H,m, E isomer), 8.32-8.44(0.9H,m, Z isomer). OH signal was not observed. MS m/z: 479 (M+1)
Example 95 -4-(4-Chloro-3-trifuluoromethylphenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0142] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-chloro-3-trifluoromethylphenyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.62-1.74(2H,m), 2.10(2H,dt), 2.35-2.80(8H,m), 2.42(1H, brs), 3.76(3H,s), 5.26(2H,brs), 6.07(0.9H,t, Z isomer), 6.03(0.1H,t, E isomer), 6.82-6.71(3H,m), 7.24(1H,dd), 7.43(1H,d), 7.56(1.8H,dd, Z isomer), 7.65(0.2,H,dd, E isomer) 7.83(1H,d), 8.36(0.1H,dd, E isomer), 8.44(0.9H,dd, Z iosmer),
MS m/z: 545(M+1)
Example 96 -4-(3,5-dichlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0143] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(3,5-dichlorophenyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.58-2.22(5H,m), 2.38-2.77(8H,m), 3.76(3H,s), 5.26(2H,brs), 5.92(0.1H,t, E isomer), 6.07(0.9H,t, Z isomer), 6.83-6.71(3H,m), 7.19-7.42(4H,m), 7.56(0.9H,dd, Z isomer), 7.68(0.1H,dd, E isomer), 8.38(0.1H,dd, E isomer), 8.45(0.9H,dd, Z isomer).
MS m/z: 512(M+1)
Example 97 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(2-pyridyl)piperidin-4-ol
[0144] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(2-pyridyl)-4-hydroxypiperidine
1H-NMR (CDCl3) δ: 1.54-1.65(2H,m), 2.06(2H,dt), 2.07(1H,brs), 2.35-2.62(7H,m), 2.73-2.87(2H,m), 3.78(3H,s), 5.28(2H, brs), 6.08(1H,t), 6.72-6.85(3H,m), 7.14-7.29(2H,m), 7.57(1H,d), 7.70(1H,dd), 8.48(2H,dd).
MS m/z: 444(M+1)
Example 98 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(3-pyridyl)piperidin-4-ol
[0145] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(3-pyridyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.65-1.78(2H,m), 2.08(2H,dt), 2.37-2.88(7H,m), 2.63-2.79(2H,m), 3.78(3H,s), 5.28(2H, brs), 6.02(0.1H,t, E isomer), 6.07(0.9H,t, Z isomer), 6.70-6.84(3H,m), 7.22-7.32(3H,m), 7.56(1H,dd), 7.77(1H,dd), 8.46(0.9H,d), 8.57(0.1H,dd, E isomer), 8.73(1H,dd).
MS m/z: 444(M+1)
Example 99 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-pyridyl)piperidin-4-ol
[0146] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-pyridyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.58-1.72(2H,m), 2.03(2H,dt), 2.34-2.89(8H,m), 2.96(1H,brs), 3.76(3H,s), 5.25(2H, brs), 6.06(1H,t), 6.72-6.83(3H,m), 7.24(1H,dd), 7.37(2H,dd), 7.56(1H,dd), 8.45(1H,dd), 8.48(2H,dd).
MS m/z: 444(M+1)
Example 100 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-trifluoromethylphenyl)piperidin-4-ol
[0147] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-trifluoromethylphenyl)-4-hydroxypiperidine.
1H-NMR (CDCl3) δ: 1.64-1.75(2H,m), 2.01(1H, brs), 2.16(2H,dt), 2.38-2.86(8H,m), 3.76(3H,s), 5.26(2H,brs), 6.04(1H,t), 6.72-6.84(3H,m), 7.23(1H,dd), 7.56(5H,m), 8.42(1H,dd).
MS m/z: 511(M+1)
Example 101 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0148] The titled compound was prepared by following the procedure of example 2, step 2, but replacing 4- (4-chlorophenyl)-4-hydroxypiperidine with 4-(4-chlorophenyl)piperidine.
1H-NMR (CDCl3) δ: 1.62-1.92(4H,m), 1.94-2.18(2H,m), 2.28-2.64(5H,m), 2.99(2H,m), 5.25(2H,brs), 6.00(1H,t), 6.60-6.82(3H,m), 7.02-7.36(5H,m), 7.50(1H,dd), 8.47(1H,dd). OH signal was not observed.
MS m/z: 447(M+1)
Example 102 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0149] The titled compound was prepared by following the procedure of example 4, but replacing the product of example 44 with the product of example 151.
1H-NMR (CDCl3) δ: 1.40(3H,t), 1.52-2.14(6H,m), 2.30-2.57(5H,m), 2.94(2H,m), 4.00(2H,q), 5.28(2H,brs), 6.07(1H,t), 6.68-6.86(3H,m), 7.05-7.36(5H,m), 7.58(1H,m), 8.49(1H,m).
MS m/z: 475(M+1)
Example 103 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxycarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0150] The titled compound was prepared by following the procedure of example 6, but replacing the product of example 1 with the product of example 101.
1H-NMR (CDCl3) δ: 1.29(3H,t), 1.56-1.85(4H,m), 1.99(2H,dt), 2.28-2.55(5H,m), 2.91(2H,m), 4.27(2H,q), 4.58(2H,s), 5.28(2H,brs), 6.09(1H,t), 6.68-6.95(3H,m), 7.07-7.32(5H,m), 7.58(1H,dd), 8.49(1H,dd).
MS m/z: 533(M+1)
Example 104 -1-[3-(7-(Carboxymethyloxy-5,11-dihydro[1]benzoxepinol[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidine
[0151] The titled compound was prepared by following the procedure of example 83, but replacing the product of example 6 with the product of example 103.
1H-NMR (CD3OD) δ: 1.82-2.17(4H,m), 2.69(2H,m), 2.86(1H,m), 3.07(2H,m), 3.30(2H,m), 3.57(2H,m), 4.57(2H,s), 5.21(2H,brs), 6.10(1H,t), 6.70-7.04 (3H,m), 7.16-7.38(4H,m), 7.44(1H,m), 7.77(1H,m), 8.47(1H,m). COOH signal was not observed.
MS m/z: 505(M+1)
Example 105 -4-(4-Chlorophenyl)-1- [3-(5,11-dihydro-7-dimethylaminocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0152] The titled compound was prepared by following the procedure of example 84, but replacing the product of example 83 with the product of example 104.
1H-NMR (CDCl3) δ: 1.58-1.92(4H,m), 2.04(2H,m), 2.30-2.68(5H,m), 2.93(2H,m), 2.98(3H,s), 3.08(3H,s), 4.65(2H,s), 5.28(2H,brs), 6.07(1H,t), 6.70-6.98(3H,m), 7.08-7.36(5H,m), 7.60(1H,m), 8.50(1H,m).
MS m/z: 532(M+1)
Example 106 -1-[3-(7-(2-Acetoxyethyl)oxy-5,11-dihydro [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0153] The titled compound was prepared by following the procedure of example 8, but replacing the product of example 2 with the product of example 101.
1H-NMR (CDCl3) δ: 1.55-1.88(4H,m), 1.90-2.32(2H,m), 2.10(3H,s), 2.28-2.60(5H,m), 2.82-3.02(2H,m), 4.14(2H,dd), 4.41(2H,dd), 5.29(2H,brs), 6.08(1H,t), 6.72-6.90(3H,m), 7.18-7.34(5H,m), 7.57(1H,m), 8.50(1H,m).
MS m/z: 533(M+1)
Example 107 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-hydroxyethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0154] The titled compound was prepared by following the procedure of example 9, but replacing the product of example 8 with the product of example 106.
1H-NMR (CD3OD) δ: 1.66-1.98(4H,m), 2.40-2.73(5H,m), 2.82-2.94(2H,m), 3.22(2H,m), 3.84(2H,dd), 4.01(2H,dd), 5.23(2H,brs), 6.13(1H,t), 6.64-6.98(3H,m), 7.13-7.34(4H,m), 7.45(1H,m), 7.77(1H,m), 8.47(1H,m). OH signal was not observed.
MS m/z: 491(M+1)
Example 108 -4-(4-Chlorophenyl) -1- [3-(5, 11-dihydro-7-(1-ethoxycarbonyl-1-methylethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0155] The titled compound was prepared by following the procedure of example 88, but replacing the product of example 2 with the product of example 101.
1H-NMR (CDCl3) δ: 1.28(3H,t), 1.56(6H,s), 1.56-1.85(4H,m), 1.97(2H,dt), 2.28-2.55(5H,m), 2.93(2H,m), 4.24(2H,q), 5.28(2H,brs), 6.04(1H,t), 6.62-6.95(3H,m), 7.07-7.32(5H,m), 7.57(1H,dd), 8.50(1H,dd).
MS m/z: 561(M+1)
Example 109 -1-[3-(7-(1-Carboxy-1-methylethyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidine
[0156] The titled compound was prepared by following the procedure of example 83, but replacing the product of example 48 with the product of example 108.
1H-NMR (CD3OD) δ: 1.50(6H,s), 1.82-2.18(4H,m), 2.70(2H,m), 2.87(1H,m), 3.12(2H,m), 3.30 (2H,m), 3.60(2H,m), 5.25(2H,brs), 6.07(1H,t), 6.67-7.04(3H,m), 7.16-7.38(4H,m), 7.58(1H,m), 7.96(1H,m), 8.52(1H,m). COOH signal was not observed.
MS m/z: 533 (M+1)
Example 110 -1-[3-(8-Bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidine
[0157] The titled compound was prepared by following the procedure of example 23, but replacing the product of example 3, step 2 with the product of example 12, step 1.
1H-NMR (CDCl3) δ: 1.50-1.86(4H,m), 1.98(2H,m), 2.26-2.60(5H,m), 2.88(2H,m), 5.30(2H,brs), 6.09(1H,t), 6.96-7.36(8H,m), 7.57(1H,dd), 8.51(1H,dd).
MS m/z: 509, 511(M+1)
Example 111 -1-[3-(8-Carboxy-5,11-dihydro [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidine
[0158] To a solution of 1-[3-(8-Bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidine (Example 111) (130 mg) in THF(1.0 ml) was added 1.6M n-butyllithium hexane solution (0.17 ml) at -78°C. After stirring 10 minutes at the same temperature, CO2 (dry-ice) was added to the mixture. After being warmed to ambient temperature, the mixture was stirred for 30 minutes at the same temperature. The mixture was concentrated in vacuo. The resulting oil was purified by silica gel chromatography eluted with dichloromethane -methanol (5:1) to give the titled compound (50mg)
1H-NMR (CD3OD) δ: 1.55-1.95(4H,m), 2.17(2H,dt), 2.32-2.78(5H,m), 3.00(2H,m), 5.30(2H,brs), 6.19(1H,t), 7.08-7.54(8H,m), 7.76(1H,dd), 8.45(1H,dd) COOH signal was not observed .
MS m/z: 475(M+1)
Example 112 -1-[3-(7-Bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0159] The titled compound was prepared by following the procedure of example 3, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 8-bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDCl3) δ: 1.60-1.71(3H,m), 1.98-2.09(2H,m), 2.34-2.69(8H,m), 5.32(2H,brs), 6.13(1H,t), 6.73(1H,d), 7.22-7.44(7H,m), 7.57(1H,dd), 8.52(1H,dd).
MS m/z: 525, 527(M+1)
Example 113 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0160] The titled compound was prepared by following the procedure of example 3, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro-7-ethyl[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDCl3) δ: 1.23(3H,t), 1.52(1H,brs), 1.66-1.71(2H,m), 1.98-2.06(2H,m), 2.35-2.70(11H,m), 5.31(2H,brs), 6.09(1H,t), 6.79(1H,d), 7.01(1H,dd), 7.11(1H,d), 7.25-7.44(5H,m), 7.58(1H,dd), 8.49(1H,dd).
MS m/z: 475(M+1)
Example 114 -4-(4-Chlorophenyl)-1-[3-(5, 11-dihydro-8-vinyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0161] The titled compound was prepared by following the procedure of example 3, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro-8-vinyl[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDCl3) δ: 1.66-1.71(3H,m), 2.00-2.10(2H,m), 2.36-2.70(8H,m), 5.22(2H,d), 5.34(2H,brs), 5.70(1H,d), 6.11(1H,t), 6.61(1H,dd), 6.89(1H,d), 6.99(1H,dd), 7.24-7.44(6H,m), 7.58(1H,dd), 8.49(1H,dd).
MS m/z: 473(M+1)
Example 115 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-8-ethyl [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0162] A mixture of the product of example 114 (100 mg) and Pd-C (20 mg) in ethanol(2 ml) stirred under a hydrogen balloon at room temperature for 1 hour. The mixture was filtered through the celite and distilled off under reduced pressure. The residue was purified by preparative thin layer chromatography eluting with chloroform-methanol (15:1) to give the titled compound (50 mg).
1H-NMR (CDCl3) δ: 1.22(3H,t), 1.55-1.77(3H,m), 2.00-2.13(2H,m), 2.33-2.74(10H,m), 5.32(2H,brs), 6.07(1H,t), 6.70(1H,d), 6.78(1H,dd), 7.19-7.44(6H,m), 7.57(1H,dd), 8.49(1H,dd).
MS m/z: 475(M+1)
Example 116 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-9-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0163] The titled compound was prepared by following the procedure of example 3, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro-9-methoxy[1]benzoxepino[2,3-b]pyridin-5-one. 1H-MMR (CDCl3) δ: 1.65-1.70(2H,m), 1.95-2.06(2H,m), 2.15(1H,brs), 2.37-2.67(8H,m), 3.83(3H,s), 5.43(2H,brs), 6.09(1H,t), 6.79-6.91(3H,m), 7.22-7.43(5H,m), 7.57(1H,dd), 8.44(1H,dd).
MS m/z: 477(M+1)
Example 117 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-trifluoromethanesulfonyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0164] To a solution of product of example 2 (1.0 g) in pyridine (10 ml) was added trifluoromethanesulfonic acid anhydride (0.55 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. Water and diethyl ether were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography eluting with ethyl acetate-methanol (10:1) to give the titled compound (1.1 g).
1H-NMR (CDCl3) δ: 1.56(1H,brs), 1.66-1.71(2H,m), 1.97-2.09(2H,m), 2.35-2.69(8H,m), 5.35(2H,brs) 6.15(1H,t), 6.88(1H,d), 7.05(1H,dd), 7.21-7.44(6H,m), 7.60(1H,dd), 8.54(1H,dd).
MS m/z: 595(M+1)
Example 118 -1-[3-(7-Allyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0165] A mixture of the product of example 117 (240 mg), allyltributyltin (0.19 ml), dichlorobis(triphenylphosphine)palladium(II) (30 mg) and lithium chloride (76 mg) in dimethylformamide (3 ml) was heated under argon at 120°C for 2 hours. Aqueous ammonium fluoride solution and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography eluting with chloroform-methanol (10:1) to give the titled compound (180 mg).
1H-NMR (CDCl3) δ: 1.62-1.72(.3H,m), 2.03-2.11(2H,m), 2.39-2.73(8H,m), 3.31(2H,d), 5.04-5.11(2H,m), 5.29(2H,brs), 5.87-6.02(1H,m), 6.06(1H,t), 6.77(1H,d), 6.99(1H,dd), 7.10(1H,d), 7.23-7.43(5H,m), 7.57(1H,dd), 8.40(1H,dd).
Example 119 -1-[3-(7-(2-t-Butoxycarboxy)ethenyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0166] A mixture of the product of example 117 (1.7 g), t-butyl acrylate (0.85 ml), triethylamine (2.5 ml), 1,1'-bis(diphenylphosphino)ferrocene (250 mg) and palladium(II) diacetate (33 mg) in dimethylformamide (3 ml) was heated under argon at 90°C for 24 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate The solvent was distilled off under reduced pressure, and the residue was purified.by silica gel chromatography eluting with ethyl acetate-methanol (30:1) to give the titled compound (780 mg).
1H-NMR (CDCl3) δ: 1.45(9H,s), 1.63-1.71(3H,m), 1.98-2.10(2H,m), 2.35-2.72(8H,m), 5.35(2H,brs), 6.15(1H,t), 6.26(1H,d), 6.83(1H,d), 7.22-7.44(7H,m), 7.53(1H,d), 7.58(1H,dd), 8.52(1H,dd).
Example 120 -1-[3-(7-(2-Carboxy)ethenyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0167] The product of example 119 (330 mg) was dissolved with 4N hydrochloric acid 1,4-dioxane solution (4 ml), and stirred at room temperature for 1 hour. The solvent was distilled off under reduced pressure. Water was added to the residue, and neutralized with sodium hydroxide solution. The precipitation was filtered to give the titled compound (190 mg).
1H-NMR (DMSO-d6) δ: 1.45-1.52(2H,m), 1.72-1.84(2H,m), 2.25-2.58(8H,m), 5.25(2H,brs), 6.28(1H,t), 6.43(1H,d), 6.82(1H,d), 7.34-7.60(8H,m), 7.75(1H,dd), 8.52(1H,dd).
Example 121 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-propargyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0168] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with propargyl chloride.
1H-NMR (CDCl3) δ: 1.66-1.71(2H,m), 1.79(1H,brs), 1.99-2.10(2H,m), 2.35-2.71-(9H,m), 4.66(2H,d), 5.28(2H,brs), 6.10(1H,t), 6.80-6.93(3H,m), 7.24-7.46(5H,m), 7.59(1H,dd), 8.48(1H,dd).
MS m/z: 501(M+1)
Example 122 -4-(4-Chlorophenyl)-1-[3-(7-cyclopentoxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0169] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with cyclopentyl bromide.
1H-NMR (CDCl3) δ: 1.54-2.18(13H,m), 2.41-2.72(8H,m), 4.66-4.73(1H,m), 5.27(2H,brs), 6.08(1H,t). 6.70-6.87(3H,m), 7.23-7.44(5H,m), 7.58(1H,dd), 8.49(1H,dd).
MS m/z: 531(M+1)
Example 123 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-methoxyethyl)oxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0170] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with 2-methoxyethyl chloride.
1H-NMR (CDCl3) δ: 1.66-1.75(3H,m), 2.00-2.11(2H,m), 2.36-2.71(8H,m), 3.45(3H,s), 3.71-3.75(2H,m), 4.07-4.11(2H,m), 5.27(2H,brs), 6.09(1H,t), 6.75-6.91(3H,m), 7.23-7.44(5H,m), 7.57(1H,dd), 8.48(1H,dd).
MS m/z: 521(M+1)
Example 124 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-dimethyaminocarbonyl-1-methylethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0171] The titled compound was prepared by following the procedure of example 84, but replacing the product of example 83 with the product of example 89.
1H-NMR (CDCl3) δ: 1.59(6H,s), 1.67-1.72(2H,m), 1.99-2.09(2H,m), 2.36-2.70(9H,m), 2.96(3H,s), 3.21(3H,s), 5.25(2H,brs), 6.02(1H,t), 6.60-6.77(3H,m), 7.24-7.44(5H,m), 7.58(1H,dd), 8.44(1H,dd).
MS m/z: 576(M+1)
Example 125 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-ethoxycarbonylethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0172] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with ethyl 2-bromopropionate.
1H-NMR (CDCl3) δ: 1.25(3H,t), 1.59(3H,d), 1.65-1.70(2H,m), 1.98-2.08(2H,m), 2.35-2.68(8H,m), 2.80(1H,brs), 4.21(2H,q), 4.68(1H,q), 5.24(2H,brs), 6.07(1H,t), 6.68-6.79(2H,m), 6.88(1H,d), 7.22-7.44(5H,m), 7.56(1H,dd), 8.40(1H,dd).
Example 126 -1-[3-(7-(1-Carboxyethyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0173] The titled compound was prepared by following the procedure of example 83, but replacing product of example 48 with product of example 125.
1H-NMR (DMSO-d6) δ: 1.46(3H,d), 1.58-1.63(2H,m), 1.98-2.06(2H,m), 2.41-2.45(2H,m), 2.72-2.86(6H,m), 4.74(1H,q), 5.18(2H,brs), 6.11(1H,t), 6.73(2H,s), 6.84(1H,s), 7.36-7.47(5H,m), 7.73(1H,dd), 8.50(1H,dd).
MS m/z: 535(M+1)
Example 127 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-ethoxycarbonyl)cyclobutoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0174] The titled compound was prepared by following the procedure of example 4, but replacing ethyl iodide with ethyl 2-bromocyclobutanecarboxylate.
1H-NMR (CDCl3) δ: 1.19(3H,t), 1.67-1.71(2H, m), 1.92-2.11(5H,m), 2.33-2.77(12H,m), 4.21(2H,q), 5.25(2H,brs), 6.05(1H,t), 6.47(1H,dd), 6.70(1H,d), 6.73(1H,d), 7.23-7.44(5H,m), 7.55(1H,dd), 8.44(1H,dd).
Example 128 -1-[3-(7-(1-Carboxy)cyclbutoxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0175] The titled compound was prepared by following the procedure of example 83, but replacing product of example 6 with product of example 127.
1H-NMR (DMSO-d6) δ: 1.60-1.65(2H,m), 1.86-2.08(4H,m), 2.24-2.90(12H,m), 5.17 (2H,brs), 6.05(1H,t), 6.50(1H,dd), 6.66(1H,d), 6.73(1H,d), 7.37-7.48(5H,m), 7.74(1H,dd), 8.51(1H,dd).
MS m/z: 561(M+1)
Example 129 -1-[3-(7-Carbamoylmethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol
[0176] The titled compound was prepared by following the procedure of example 84, but replacing dimethylamine hydrochloride with ammonium hydroxide.
1H-NMR (CDCl3) δ: 1.66-1.71(2H,m), 1.98-2.09(2H,m), 2.21(1H,brs), 2.38-2.70(8H,m), 4.45(2H,s), 5.28(2H,brs), 6.09(1H,t), 6.11(1H,brs), 6.58(1H,brs), 6.74-6.85(3H,m), 7.24-7.44(5H,m), 7.58(1H,dd), 8.47(1H,dd).
MS m/z: 520(M+1)
Example 130 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methylaminocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0177] The titled compound was prepared by following the procedure of example 84, but replacing dimethylamine hydrochloride with methylamine.
1H-NMR (CDCl3) δ: 1.67-1.72(2H,m), 1.99-2.10(2H,m), 2.36-2.70(9H,m), 2.89(3H,d), 4.45(2H,s), 5.28(2H,brs), 6.08(1H,t), 6.66(1H,brs), 6.73-6.84(3H,m), 7.25-7.45(5H,m), 7.58(1H,dd), 8.47(1H,dd).
MS m/z: 534(M+1)
Example 131 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl] -4-(4-hydroxyphenyl)piperidine
[0178] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-hydroxyphenyl)piperidine.
1H-NMR (CDCL3) δ: 1.52-1.88(4H,m), 2.01(2H,dt), 2.28-2.60(5H,m), 2.93(2H,m), 3.79(3H,s), 5.28(2H,brs), 6.08(1H,t), 6.68-6.88(3H,m), 7.05-7.36(5H,m), 7.58(1H,dd), 8.50(1H,dd).
MS m/z: 461(M+1)
Example 132 -1-[3- (5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl] 4-(2-hydroxyphenyl)piperidine
[0179] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(2-hydroxyphenyl)piperidine.
1H-NMR (CDCl3) δ: 1.78-1.92(4H,m), 2.12-2.25(2H,m), 2.32-2.70(4H,m), 2.80-2.97(1H,m), 3.01-3.15(2H,m), 3.77(3H,s), 3.78.(1H,brs), 5.28(2H,brs), 6.03(1H,t), 6.74-6.86(4H,m), 7.05(1H,dd), 7.11(1H,dd), 7.23-7.28(2H,m), 7.56(1H,dd), 8.48(1H,dd) OH signal was not observed.
MS m/z: 443(M+1)
Example 133 -4-(7-Chloro-1,2-benzisoxazol-3-yl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0180] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(7-chloro-1,2-benzisoxazol-3-yl) piperidine. This piperidine was prepared by the same method described in J. Med. Chem. 28:761-769 (1985).
1H-NMR (CDCl3) δ: 1.94-2.20 (6H,m), 2.30-2.60(4H,m), 2.86-3.14(3H,m), 3.79(3H,s), 5.29(2H,brs), 6.10(1H,t), 6.70-6.88(3H,m), 7.22(1H,t), 7.27(1H,dd), 7.50(1H,dd), 7.57-7.68(2H,m), 8.49(1H,dd).
Example 134 -4-(7-Chloroindol-3-yl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0181] The titled compound was prepared by following the procedure of example 3, step 3, but replacing. 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(7-chloroindol-3-yl)piperidine. This piperidine was prepared by the same method described in J. Med. Chem. 36:4006-4014 (1993) and following hydrogenation described in Example 58, step 3.
1H-NMR(CDCl3) δ: 1.66-1.88(2H,m), 1.92-2.22(4H,m), 2.32-2.63(4H,m), 2.78(1H,m), 2.97(2H,m), 3.79(3H,s), 5.29(2H,brs), 6.09(1H,t), 6.70-6.87(3H,m), 6.97-7.07(2H,m), 7.12-7.30(2H,m), 7.52(1H,m), 7.59(1H,dd), 8.45(1H,brs), 8.50(1H,dd).
Example 135 -4-Azido-4-(4-chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine
[0182] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-azido-4-(4-chlorophenyl) piperidine.
1H-NMR (CDCL3) δ: 1.88(2H,m), 2.55-2.85(4H,m), 3.00-3.30(6H,m). 3.75(3H,s), 5.19(2H,brs), 5.97(1H,t), 6.68-6.65(3H,m), 7.20-7.46(5H,m), 7.63(1H,dd), 8.35(1H,dd).
MS m/z: 477(M+1-N2+H2)
Example 136 -Methyl 1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-phenylpiperidin-4-carboxylate
[0183] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with methyl 4-phenylpiperidin-4-carboxylate.
1H-NMR (CDCl3) δ: 1.82-2.15 (4H,m), 2.28-2.60(6H,m), 2.78-2.82(2H,m), 3.62(3H,s), 3.68(3H,s), 5.26(2H,brs), 5.95(0.1H,t, E isomer), 6.05(0.9H,t, Z isomer), 6.82-6.70(3H,m), 7.33-7.22(6H,m), 7.65(0.1H,dd, Z isomer), 7.55(0.9H,dd, Z isomer), 8.39(0.1H, dd, E isomer), 8.48(0.9H,dd, Z isomer).
MS m/z: 485(M+1)
Example 137 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-phenylpiperidin-4-carboxylic acid
[0184] The titled compound was prepared by following the procedure of example 83, but replacing product of example 6 with product of example 136.
1H-NMR (CD3OD) δ: 2.16-2.23(2H,m), 2.69-2.91(4H,m), 3.00-3.16(2H,m), 3.37-3.25(2H,m), 3.68-3.73(2H,m), 3.76(3H,s), 5.34(2H,brs), 6.24(1H,t), 6.70-7.04(3H,m), 7.26-7.55(5H,m), 7.79-7.89(1H,m), 8.21-8.34(1H,m), 8.56-8.62(0.1H,m), 8.63-8.77(0.9H,m),
MS m/z: 471(M+1)
Example 138 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-1,2,3,6-tetrahydropyridine
[0185] The titled compound was prepared by following the procedure of example 2, step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine.
1H-NMR (CDCl3) δ: 2.37-2.72(8H,m), 3.07(2H,m), 5.25(2H,brs), 6.00(1H,m), 6.07(1H,t), 6.60-6.78(3H,m), 7.18-7.47(5H,m), 7.56(1H,dd), 8.50(1H,dd), OH signal was not observed.
MS m/z: 445(M+1)
Example 139 -4-(4-Chlorophenyl)-1-[3-(5, 11-dihydro-7-methoxy [1] benzoxepino [2,3-b]pyridin-5-ylidene)propyl]-1,2,3,6-tetrahydropyridine
[0186] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4- (4-chlorophenyl)-4-hydroxypiperidine with 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine.
1H-NMR (CDCl3) δ: 2.37-2.72(8H,m), 3.06(2H,m), 3.78(3H,s), 5.27(2H,brs), 5.99(1H,m), 6.10(1H,t), 6.72-6.90(3H,m), 7.20-7.44(5H,m), 7.60(1H,dd), 8.50(1H,dd).
MS m/z: 459(M+1)
Example 140 -4-(7-Chloroindol-3-yl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-1,2,3,6-tetrahydropyridine.
[0187] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(7-chloroindol-3-yl)-1,2,3,6-tetrahydropyridine. This piperidine was prepared by the.same method described in J. Med. Chem. 36:4006-4014 (1993).
1H-NMR (CDCl3) δ: 2.37-2.76(8H,m), 3.14(2H,m), 3.78(3H,s), 5.29(2H,brs), 6.02-6.23(2H,m), 6.67-6.90(3H,m), 7.05(1H,dd), 7.12-7.33(3H,m), 7.60(1H,dd), 7.77(1H,m), 8.50(1H,dd), 9.06(1H,br s).
Example 141 -5-Chloro-1'-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]spiro[isobenzofuran-1(3H),4'-piperidine]
[0188] The titled compound was prepared by following the procedure of example 2, step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 5-chlorospiro[isobenzofuran-1(3H),4'-piperidine].
1H-NMR (CDCl3) δ: 1.66-1.71(2H,m), 1.79-1.91(2H,m), 2.26-2.73(8H,m), 4.99(2H,s), 5.22(2H,brs), 6.07(1H,t), 6.63-6.70(2H,m), 6.76(1H,d), 7.06(1H,d), 7.19-7.32(3H,m), 7.60(1H,dd), 8.47(1H,dd), 8.63(1H,s).
MS m/z: 475(M+1)
Example 142 -5-Chloro-1'-[3-(5,11-dihydro-7-(2-methoxyethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]spiro[isobenzofuran-1(3H),4'-piperidine]
[0189] The titled compound was prepared by following the procedure of example 123, but replacing the product of example 2 with the product of example 141.
1H-NMR (CDCl3) δ: 1.69-1.74(2H,m), 1.83-1.94(2H,m), 2.31-2.76(8H,m), 3.45(3H,s), 3.72-3.75(2H,m), 4.08-4.11(2H,m), 5.00(2H,s), 5.28(2H,brs), 6.09(1H,t), 6.74-6.82(2H,m), 6.89(1H,d), 7.04(1H,d), 7.17-7.28(3H,m), 7.57(1H,dd), 8.49(1H,dd).
MS m/z: (M+1)
Example 143 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-dimethylaminocarbonyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0190] The titled compound was prepared by following the procedure of example 84, but replacing the product of example 83 with the product of example 68.
1H-NMR (CDCl3) δ: 1.65-1.70(2H,m), 1.99-2.09(3H,m), 2.32-2.69(8H,m), 2.17(3H,s), 5.35(2H,brs), 6.15(1H,t), 6.82(1H,d), 7.19(1H,dd), 7.28-7.46(6H,m), 7.58(1H,dd), 8.49(1H,dd).
Example 144 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1,1-dimethyl-2-hydroxyethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0191] To a solution of product of example 88 (500 mg) in methanol (5 ml) was added sodium borohydride (330 mg), and the mixture was heated to reflux for 1 hour. The mixture was distilled off under reduced pressure. Water and ethyl acetate were added to the residue, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography eluting with chloroform-methanol (10:1) to give the titled compound (440 mg).
1H-NMR (CDCl3) δ: 1.26 (6H, s), 1.66-1.70(2H, m), 1.79(1H.brs), 2.00-2.08(2H,m), 2.37-2.70(9H,m), 3.58(2H,s), 5.30(2H,brs), 6.05(1H,t), 6.75-6.84(2H,m), 6.91(1H,d), 7.26-7.44(5H,m), 7.58(1H,dd), 8.49(1H,dd).
MS m/z: 535(M+1)
Example 145 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2,2-dimethyl-2-hydroxyethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol
[0192] To a solution of product of example 6 (500 mg) in tetrahydrofuran (5 ml) was added 0.95M methylmagnesium bromide tetrahydrofuran solution (3.8 ml) at 0°C, and the mixture was stirred at room temperature for 20 minutes. Aqueous ammonium chloride solution and ethyl acetate were added to the mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography eluting with chloroform-methanol (10:1) to give the titled compound (360 mg).
1H-NMR (CDCl3) δ: 1.34(6H,s), 1.58(1H,brs), 1.65-1.71(2H,m), 1.99-2.10(2H,m), 2.25(1H,brs), 2.36-2.71(8H,m), 3.77(2H,s), 5.28(2H,brs), 6.09(1H,t), 6.74-6.86(3H,m), 7.24-7.44(5H,m), 7.57(1H,dd), 8.49(1H,dd).
MS m/z: 535(M+1)
Example 179 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidine)propyl]-4-(indol-3-yl)-piperidine
[0193] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(indol-3-yl)-piperidine. This piperidine was prepared by the same method described in J. Med. Chem. 36:4006-4014 (1993) and follow hydrogenation described in Example 58, step 3.
1H-NMR(CDCl3) δ: 1.65-1.93(2H,m), 1.94-2.28(4H,m), 2.34-2.70(4H,m), 2.81(1H,m), 2.96(2H,m), 3.78(3H,s), 5.28(2H,brs), 6.09(1H,t), 6.70-7.42(8H,m), 7.53-7..72 (2H,m), 8..28 (1H,brs), 8.49(1H,m).
Example 180 -1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidine)propyl]-4-(indol-3-yl)-1,2,3,6-tetrahydropyridine.
[0194] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(indol-3-yl)-1,2,3,6-tetrahydropyridine. This tetrahydropyridine was prepared by the same method described in J. Med. Chem. 36:4006-4014 (1993).
1H-NMR (CDCl3) δ: 2.35-2.77(8H,m), 3.06-3.26(2H,m), 3.78(3H,s), 5.29(2H,brs), 6.05-6.22(2H,m), 6.70'-6.88(3H,m), 7.07-7.38(5H,m), 7.60(1H,dd), 7.87(1H,m), 8.42(1H,brs), 8.50(1H,m).
Example 181 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(3-(ethoxycarbonyl)propyloxy[1]benzoxipino[2,3-b]pyridin-5-ylidine)propyl)piperidine
[0195] The titled compound was prepared by following the procedure of example 103, but replacing ethyl bromoacetate with ethyl 4-bromobutyrate.
1H-NMR (CDCL3) δ: 1.26(3H,t), 1.56-1.85(4H,m), 2.01(2H,dt), 2.09(2H,quint), 2.30-2.60(7H,m), 2.93(2H,m), 3.98(2H.t), 4,15(2H,q), 5.28(2H,brs), 6.07(1H,t), 6.68-6.86(3H,m), 7.07-7.33(5H,m),7.58(1H,dd), 8.50(1H,dd).
MS m/z: 561(M+1)
Example 182 -1-[3-(7-(3-Carboxypropyl)oxy-5,11-dihydro-[1]benzoxepino[2,3-b]pyridin-5-ylidine)propyl]-4-(4-chlorophenyl)-piperidine
[0196] The titled compound was prepared by following the procedure of example 83, but replacing the product of example 6 with the product of example 181.
1H-NMR (CD3OD) δ: 1.92-2.20(6H,m), 2.48(2H,t), 2.70-3.02(3H,m), 3.06-3.45(4H,m), 3.66(2H,m), 4.01(2H,t), 5.48(2H,brs), 6.36(1H,t), 6.85(2H,s), 7.00(1H,s), 7.20-7.40(4H,m), 8.11(1H,dd), 8.64(1H,d), 8.81(1H,d). COOH signal was not observed.
MS m/z: 533(M+1)
Example 183 -1'-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidine)propyl)-6-methylspiro[4H-3,1-benzoxazine-4,4'-piperidine]-2(1H)-one
[0197] The titled compound was prepared by following the procedure of example 3, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 6-methylspiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one.
1H-NMR (CDCl3) δ: 1.99-2.06(2H,m), 2.29(3H,s), 2.32-2.69(10H,m), 3.77(3H,s), 5.27(2H,brs), 6.08(1H,t), 6.69-6.83(4H,m), 6.94(1H,s), 7.02(1H,d), 7.25(1H,dd), 7.55(1H,dd), 8.48(1H,dd), 8.56(1H,s).
MS m/z: 498(M+1)
or physiologically acceptable salt thereof, wherein:
n is an integer from one to four;
M is >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH, -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group), -O-C(O)-(substituted aliphatic group), -C(O)O-(aliphatic group), -C(O)O-(substituted aliphatic group), -CN, -COOH, -CO-NR3R4 or -NR3R4; or R1 is a covalent bond between the ring atom M and an adjacent carbon atom in the ring which contains M;
R2 is -OH, an acyl group, a substituted acyl group, -NR5R6, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
R3, R4, R5 and R6 are independently -H, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; or
R1 and R2, R3 and R4, or R5 and R6 taken together with the atom to which they are bonded, form a substituted or unsubstituted non-aromatic heterocyclic ring;
said acyl group is an aliphatic carbonyl, aromatic carbonyl, aliphatic sulfonyl or aromatic sulfonyl;
Z is:
wherein:
X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NRc-CH2-, -CH2-NRc-, -SO-CH2-,-CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NRc-CO- or -CO-NRc-;
Rc is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group; Ring A and Ring B are independently substituted or unsubstituted; said substituted aliphatic group comprises one or more substituents selected from the group consisting of an electron withdrawing group, halo, azido, -COOH,
-OH, -CONR14R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group), -Q-(substituted aromatic group), -Q-(CH2)p-(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic goup), -Q-(CH2)p-(non-aromatic heterocyclic group), oxo, epoxy, non-aromatic heterocycle, benzyl, substituted benzyl, aromatic group and substituted aromatic group;
said substituted benzyl group, substituted aromatic group, and Ring A or Ring B when substituted comprise one or more substitutents selected from the group consisting of an electron withdrawing group, halo, azido, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group), -Q-(substituted aromatic group), -Q-(CH2)p-(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic group), -Q-(CH2)p-(non-aromatic heterocyclic group), aliphatic group and substituted aliphatic group; said substituted non-aromatic heterocyclic group comprises one or more substitutents selected from the group consisting of an electron withdrawing group, halo, azido, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group), -Q-(substituted aromatic group), -Q-(CH2)p-(substituted or unsubsdtuted aromatic group), -Q-(non-aromatic heterocyclic group), -Q-(CH2)p-(non-aromatic heterocyclic group), aliphatic group, substituted aliphatic group, =O, =S, =NH, =N(aliphatic), =N(aromatic) and =N(substituted aromatic);
R20, R21 and R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or -NHC(O)-O-(non-aromatic heterocyclic group); or
R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
t is an integer from zero to three;
u is zero or one;
p is one to five;
Q is -O-, -S-, -S(O)-, -S(O)2-, -OS(O)2-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)C(O)-O-, -O-C(O)C(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -NH-C(O)-NH-, -S(O)2NH-, -NHS(O)2-, -N(R23)-, -C(NR23)NHNH-, -NHNHC(NR23)-, -NR24C(O)- or -NR24S(O)2-;
R23 is -H, an aliphatic group, a benzyl group, an aryl group or non-aromatic heterocyclic group;
R24 and R25 are independently -H, -OH, an aliphatic group, a substituted aliphatic group, a benzyl group, an aryl group or non-aromatic heterocyclic group;
said aliphatic group is a saturated or unsaturated C1-C20 hydrocarbon;
said electron withdrawing group is alkylimino, alkylsulfonyl, carboxamido, carboxylic alkyl ester, -CH=NH or -NO2;
the heterocycle of said non-aromatic heterocyclic group is a 5 to 8 membered non-aromatic ring that contains one or more heteroatoms selected from the group consisting of O, N, and S; and
said aromatic group is selected from the group consisting of a C6 aromatic carbocycle, a C5 - C6 aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of O, S and N, and a C6 aromatic carbocycle or a C5 - C6 aromatic heterocycle that is fused to one or more other rings.
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or
R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
u is zero or one; and
t is an integer from zero to three.
wherein:
R40 is -OH, halogen, aliphatic group, substituted aliphatic group, -NR24R25, Q-(aliphatic group), Q-(substztuted aliphatic group), -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20;
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or
R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
Q is -NR24C(O)- or -NR24S(O)2-;
R24 and R25 are independently -H, -OH, an aliphatic group or a substituted aliphatic group;
u is zero or one; and
t is an integer from zero to 3.
and physiologically acceptable salts thereof.
or physiologically acceptable salt thereof, wherein:
n is an integer from one to four,
M is >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH, -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group), -O-C(O) -(substituted aliphatic group), -C(O)O-(aliphatic group), -C(O)O-(substituted alipatic group), -CN, -COOH, -CO-NR3R4 or -NR3R4;
R2 is -OH, an acyl group, a substituted acyl group, -NR5R6, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
R3, R4, R5 and R6 are independently -H, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; or
R1 and R2, R3 and R4, or R5 and R6 taken together with the atom to which they are bonded, form a substituted or unsubstituted non-aromatic carbocyclic or heterocyclic ring;
said acyl group is an aliphatic carbonyl, aromatic carbonyl, aliphatic sulfonyl or aromatic sulfonyl;
Z is:
wherein:
X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NRc-CH2-, -CH2-NRc-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NRc-CO- or -CO-NRc- ;
Rc is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group; Ring A and Ring B are independently substituted or unsubstituted; said substituted aliphatic group comprises one or more substituents selected from the group consisting of an electron withdrawing group, halo, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-C(O)-NR21R22, -Q-H, -Q-(alipharic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(CH2)p-(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic group), -Q-(CH2)p-(non-aromatic heterocyclic group), oxo, epoxy, non-aromatic heterocycle, benzyl, substituted benzyl, aromatic group and substituted aromatic group;
said substituted benzyl group, substituted aromatic group, and Ring A or Ring B when substituted comprise one or more substitutents selected from the group consisting of an electron withdrawing group, halo, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-C(O)-NR21R22, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(CH2)p-(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic group), -Q-(CH2)p-(non-aromatic heterocyclic group), aliphatic group and substituted aliphatic group;
said substituted non-aromatic heterocyclic group comprises one or more substitutents selected from the group consisting of an electron withdrawing group, halo, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-C(O)-NR21R22, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(CH2)p-(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic group), -Q-(CH2)p-(non-aromatic heterocyclic group), aliphatic group, substituted aliphatic group, =O, =S, =NH, =N(aliphatic), =N(aromatic) and =N(substituted aromatic);
R20, R21 and R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or -NHC(O)-O-(non-aromatic heterocyclic group); or
R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
t is an integer from zero to three;
u is zero or one;
p is one to five;
Q is -O-, -S-, -S(O)-, -S(O)2-, -OS(O)2-, -C(O)-, -OC(O)-, -C(O)O-, - C(O)C(O)-O-, -O-C(O)C(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, - NH-C(O)-NH-, -S(O)2NH-, -NHS(O)2-, -N(R23)-, -C(NR23)NHNH-, -NHNHC(NR23)-;
R23 is -H, an aliphatic group, a benzyl group, an aryl group or non-aromatic heterocyclic group;
said aliphatic group is a saturated or unsaturated C1-C20hydrocarbon;
said electron withdrawing group is alkylimino, alkylsulfonyl, carboxamido, carboxylic alkyl ester, -CH=NH or -NO2;
the heterocycle of said non-aromatic heterocyclic group is a 5 to 8 membered non-aromatic ring that contains one or more heteroatoms selected from the group consisting of O, N, and S; and
said aromatic group is selected from the group consisting of a C6 aromatic carbocycle, a C5 - C6 aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of O, S and N, and a C6 aromatic carbocycle or a C5 - C6 aromatic heterocycle that is fused to one or more other rings.
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH, -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group) or -O-C(O)-(substituted aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is:
wherein:
X1 is -CH2-CH2-, -CH2-S-, -CH2-O-, -CH2-NRc-, -CH2-SO-, -CH2-S(O)2-, -CH=CH- or -CO-NR2- ; wherein:
Rc is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group; and
Ring A and Ring B are independently substituted or unsubstituted.
oder ein physiologisch annehmbares Salz davon, worin:
n eine ganze Zahl von 1 bis 4 ist,
m >CR1R2 ist,
R1 ist -H, -OH, eine aliphatische Gruppe, -O-(aliphatische Gruppe), -O-(substituierte aliphatische Gruppe), -SH, -S-(aliphatische Gruppe), -S-(substituierte aliphatische Gruppe), -OC(O)-(aliphatische Gruppe), -O-C(O)-(substituierte aliphatische Gruppe), -C(O)O-(aliphatische Gruppe), -C(O)O-(substituierte aliphatische Gruppe), -CN, -COOH, -CO-NR3R4 oder -NR3R4; oder
R1 ist eine kovalente Bindung zwischen dem Ringatom M und einem benachbarten Kohlenstoffatom in dem Ring, der M enthält;
R2 ist -OH, eine Acylgruppe, eine substituierte Acylgruppe, -NR5R6, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische Gruppe, eine substituierte aromatische Gruppe, eine Benzylgruppe, eine substituierte Benzylgruppe, eine nicht-aromatische heterocyclische Gruppe oder eine substituierte nicht-aromatische heterocyclische Gruppe;
R3, R4, R5 und R6 sind unabhängig von einander -H, eine Acylgruppe, eine substituierte Acylgruppe, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische Gruppe, eine substituierte aromatische Gruppe, eine Benzylgruppe, eine substituierte Benzylgruppe, eine nicht-aromatische heterocyclische Gruppe oder eine substituierte nicht-aromatische heterocyclische Gruppe, oder
R1 und R2, R3 und R4 oder R5 und R6 bilden zusammen mit dem Atom, an das sie gebunden sind, einen substituierten oder unsubstituierten nicht-aromatischen heterocyclischen Ring;
die Acylgruppe ist ein aliphatisches Carbonyl, aromatisches Carbonyl, aliphatisches Sulfonyl oder aromatisches Sulfonyl;
Z ist:
worin:
X1 ist -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NRc-CH2-, -CH2-NRc-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NRc-CO- oder -CO-NRc-;
Rc ist -H, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische Gruppe, eine substituierte aromatische Gruppe, eine Benzylgruppe oder eine substituierte Benzylgruppe;
Ring A und Ring B sind unabhängig von einander substituiert oder unsubstituiert;
die substituierte aliphatische Gruppe umfasst einen oder mehrere Substituenten, ausgewählt aus der Gruppe bestehend aus einer Elektronen-abziehenden Gruppe, Halogen, Azido, -COOH, -OH, -CONR24R25, -NR24R15, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, Guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(aliphatische Gruppe), -Q-(substituierte aliphatische Gruppe), -Q-(Aryl), -Q-(aromatische Gruppe), -Q-(substituierte aromatische Gruppe), -Q-(CH2)p-(substituierte oder unsubstituierte aromatische Gruppe), -Q-(nicht-aromatische heterocyclische Gruppe), -Q-(CH2)p-(nicht-aromatische heterocyclische Gruppe), Oxo, Epoxy, nicht-aromatische heterocyclische Benzyl-, substituierte Benzyl-, aromatische Gruppe und substituierte aromatische Gruppe;
die substituierte Benzylgruppe, substituierte aromatische Gruppe und Ring A oder B, wenn sie substituiert sind, umfassen einen oder mehrere Substituenten, ausgewählt aus der Gruppe, bestehend aus einer Elektronen-abziehenden Gruppe, Halogen, Azido, -CN, -COOH, -OH, -CONR24R25, -NR24R15, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, Guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(aliphatische Gruppe), -Q-(substituierte aliphatische Gruppe), -Q-(Aryl), -Q-(aromatische Gruppe), -Q-(substituierte aromatische Gruppe), -Q-(CH2)p-(substituierte oder unsubstituierte aromatische Gruppe), -Q-(nicht-aromatische heterocyclische Gruppe), -Q-(CH2)p-(nicht-aromatische heterocyclische Gruppe), aliphatische Gruppe und substituierte aliphatische Gruppe;
die substituierte nicht-aromatische heterocyclische Gruppe umfasst einen oder mehrere Substituenten, ausgewählt aus der Gruppe bestehend aus einer Elektronen-abziehenden Gruppe, Halogen, Azido, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, Guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(aliphatische Gruppe), -Q-(substituierte aliphatische Gruppe), -Q-(Aryl), -Q-(aromatische Gruppe), -Q-(substituierte aromatische Gruppe), -Q-(CH2)p-(substituierte oder unsubstituierte aromatische Gruppe), -Q-(nicht-aromatische heterocyclische Gruppe), -Q-(CH2)p-(nicht-aromatische heterocyclische Gruppe), aliphatische Gruppe, substituierte aliphatische Gruppe, =O, =S, =NH, =N(aliphatische), =N(aromatische) und =N(substituierte aromatische);
R20, R21 und R22 sind unabhängig von einander -H, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische Gruppe, eine substituierte aromatische Gruppe, eine nicht-aromatische heterocyclische Gruppe, -NHC(O)-O-(aliphatische Gruppe) -NHC(O)-O-(aromatische Gruppe) oder NHC(O)-O-(nicht-aromatische heterocyclische Gruppe); oder
R21 und R22 bilden zusammen mit dem Stickstoffatom, an das sie gebunden sind, einen nicht-aromatischen heterocyclischen Ring;
t ist eine ganze Zahl von 0 bis 3;
u ist 0 oder 1;
p ist 1 bis 5;
Q ist -O-, -S-, -S(O)-, -S(O)2, -OS(O)2-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)C(O)-O-, -O-C(O)C(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -NH-C(O)-NH-, -S(O)2NH-, -NHS(O)2-, -N(R23)-, -C(NR23)NHNH-, -NHNHC(NR23)-, -NR24C(O)- oder -NR24S(O)2-;
R23 ist -H, eine aliphatische Gruppe, eine Benzylgruppe, eine Arylgruppe oder eine nicht-aromatische heterocyclische Gruppe;
R24 und R25 sind unabhängig von einander -H, -OH, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine Benzylgruppe, eine Arylgruppe oder eine nicht-aromatische heterocyclische Gruppe,
die aliphatische Gruppe ist eine gesättigte oder ungesättigte C1-C20-Kohlenwasserstoffgruppe;
die Elektronen-abziehende Gruppe ist Alkylimino, Alkylsulfonyl, Carboxamido, Carboxylalkylester, -CH=NH oder -NO2;
der Heterocyclus der nicht-aromatischen heterocyclischen Gruppe ist ein 5- bis 8-gliedriger nicht-aromatischer Ring, der eine oder mehrere Heteroatome enthält, ausgewählt aus der Gruppe bestehend aus O, N und S; und
die aromatische Gruppe ist ausgewählt aus der Gruppe bestehend aus einem C6-aromatischen Carbocyclus, einem C5-C6-aromatischen Heterocyclus, der ein oder mehrere Heteroatome enthält, ausgewählt aus der Gruppe bestehend aus O, S und N, und einem C6-aromatischen Carbocyclus oder einem C5-C6-aromatischen Heterocyclus, der mit einem oder mehreren anderen Ringen fusioniert ist.
R20, R21 oder R22 unabhängig von einander -H, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische Gruppe, eine substituierte aromatische Gruppe oder eine nicht-aromatische heterocyclische Gruppe; oder
R21 und R22 zusammen mit dem Stickstoffatom, an das sie gebunden sind, einen nicht-aromatischen heterocyclischen Ring bilden;
u ist 0 oder 1; und
t ist eine ganze Zahl von 0 bis 3.
worin:
R40 ist -OH, Halogen, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, -NR24R25 eine Q-(aliphatische Gruppe), eine Q-(substituierte aliphatische Gruppe), eine -0-(aliphatische Gruppe), eine -0-(substituierte aliphatische Gruppe), eine -O-(aromatische Gruppe), eine -O-(substituierte aromatische Gruppe), eine Elektronen-abziehende Gruppe, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20;
R20 , R21 oder R22 unabhängig von einander -H, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische Gruppe, eine substituierte aromatische Gruppe oder eine nicht-aromatische heterocyclische Gruppe; oder
R21 und R22 zusammen mit dem Stickstoffatom, an das sie gebunden sind, einen nicht-aromatischen heterocyclischen Ring bilden;
Q ist -NR24C(O)- oder -NR24S(O)2-;
R24 und R25 sind unabhängig von einander -H, -OH, ein aliphatische Gruppe oder eine substituierte aliphatische Gruppe;
u ist 0 oder 1; und
t ist eine ganze Zahl von 0 bis 3.
und physiologisch annehmbaren Salzen davon.
oder ein physiologisch annehmbares Salz davon, worin:
n ist eine ganze Zahl von 1 bis 4;
M ist > CR1R2;
R1 ist -H, -OH, eine aliphatische Gruppe, -O-(aliphatische Gruppe), -O-(substituierte aliphatische Gruppe), -SH, -S-(aliphatische Gruppe), -S-(substituierte aliphatische Gruppe), -OC(O)-(aliphatische Gruppe), -O-C(O)-(substituierte aliphatische Gruppe), -C(O)O-(aliphatische Gruppe), -C(O)O-(substituierte aliphatische Gruppe), -CN, -COOH, -CO-NR3R4 oder -NR3R4;
R2 ist -OH, eine Acylgruppe, eine substituierte Acylgruppe, -NR5R6, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische Gruppe, eine substituierte aromatische Gruppe, eine Benzylgruppe, eine substituierte Benzylgruppe, eine nicht-aromatische heterocyclische Gruppe oder eine substituierte nicht-aromatische heterocyclische Gruppe;
R3, R4, R5 und R6 sind unabhängig von einander -H, eine Acylgruppe, eine substituierte Acylgruppe, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische Gruppe, eine substituierte aromatische Gruppe, eine Benzylgruppe, eine substituierte Benzylgruppe, eine nicht-aromatische heterocyclische Gruppe oder eine substituierte nicht-aromatische heterocyclische Gruppe, oder
R1 und R2, R3 und R4 oder R5 und R6 bilden zusammen mit dem Atom, an das sie gebunden sind, einen substituierten oder unsubstituierten nicht-aromatischen carbocyclischen oder heterocyclischen Ring;
die Acylgruppe ist ein aliphatisches Carbonyl, aromatisches Carbonyl, aliphatisches Sulfonyl oder aromatisches Sulfonyl;
Z ist:
worin:
X1 ist -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NRc-CH2-, -CH2-NRc-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NRc-CO- oder -CO-NRc-;
Rc ist -H, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische Gruppe, eine substituierte aromatische Gruppe, eine Benzylgruppe oder eine substituierte Benzylgruppe;
Ring A und Ring B sind unabhängig von einander substituiert oder unsubstituiert; die substituierte aliphatische Gruppe umfasst eine oder mehrere Substituenten, ausgewählt aus der Gruppe bestehend aus einer Elektronen-abziehenden Gruppe, Halogen, -COOH, -OH, -CONR24R25, -NR24R15, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, Guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-C(O)NR21R22, -Q-H, Q-(aliphatische Gruppe), -Q-(substituierte aliphatische Gruppe), -Q-(Aryl), -Q-(CH2)p-(substituierte oder unsubstituierte aromatische Gruppe), -Q-(nicht-aromatische heterocyclische Gruppe), -Q-(CH2)p-(nicht-aromatische heterocyclische Gruppe), Oxo, Epoxy, nicht-aromatische heterocyclische, Benzyl-, substituierte Benzyl-, aromatische Gruppe und substituierte aromatische Gruppe;
die substituierte Benzylgruppe, substituierte aromatische Gruppe und Ring A oder B, wenn sie substituiert sind, umfassen einen oder mehrere Substituenten, ausgewählt aus der Gruppe, bestehend aus einer Elektronen-abziehenden Gruppe, Halogen, -CN, -COOH, -OH, -CONR24R25, -NR24R15, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, Guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-C(O)-NR21R22, -Q-H, -Q-(aliphatische Gruppe), -Q-(substituierte aliphatische Gruppe), -Q-(Aryl), -Q-(CH2)p-(substituierte oder unsubstituierte aromatische Gruppe), -Q-(nicht-aromatische heterocyclische Gruppe), -Q-(CH2)p-(nicht-aromatische heterocyclische Gruppe), aliphatische Gruppe und substituierte aliphatische Gruppe;
die substituierte nicht-aromatische heterocyclische Gruppe umfasst einen oder mehrere Substituenten, ausgewählt aus der Gruppe bestehend aus einer Elektronen-abziehenden Gruppe, Halogen, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, Guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-C(O)-NR21R22, -Q-H, -Q-(aliphatische Gruppe), -Q-(substituierte aliphatische Gruppe), -Q-(Aryl), -Q-(CH2)p-(substituierte oder unsubstituierte aromatische Gruppe), -Q-(nicht-aromatische heterocyclische Gruppe), -Q-(CH2)p-(nicht-aromatische heterocyclische Gruppe), aliphatische Gruppe, substituierte aliphatische Gruppe, =O, =S, =NH, =N(aliphatische), =N(aromatische) und =N(substituierte aromatische);
R20, R21 und R22 sind unabhängig von einander -H, eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische Gruppe, eine substituierte aromatische Gruppe, -NHC(O)-O-(aliphatische Gruppe), -NHC(O)-O-(aromatische Gruppe), -NHC(O)-O-(nicht-aromatische heterocyclische Gruppe); oder
R21 und R22 bilden zusammen mit dem Stickstoffatom, an das sie gebunden sind, einen nicht-aromatischen heterocyclischen Ring;
t ist eine ganze Zahl von 0 bis 3;
u ist 0 oder 1;
p ist 1 bis 5;
Q ist -O-, -S-, -S(O)-, -S(O)2, -OS(O)2-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)C(O)-O-, -O-C(O)C(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -NH-C(O)-NH-, -S(O)2NH-, -NHS(O)2-, -N(R23)-, -C(NR23)NHNH-, -NHNHC(NR23)-;
R23 ist -H, eine aliphatische Gruppe, eine Benzylgruppe, eine Arylgruppe oder eine nicht-aromatische heterocyclische Gruppe;
die aliphatische Gruppe ist ein gesättigter oder ungesättigter C1-C20-Kohlenstoff, Wasserstoff;
die Elektronen-abziehende Gruppe ist Alkylimino, Alkylsulfonyl, Carboxamido, Carboxylalkylester, -CH=NH oder -NO2;
der Heterocyclus der nicht-aromatischen heterocyclischen Gruppe ist ein 5- bis 8-gliedriger nicht-aromatischer Ring, der eine oder mehrere Heteroatome enthält, ausgewählt aus der Gruppe bestehend aus O, N und S; und
die aromatische Gruppe ist ausgewählt aus der Gruppe bestehend aus einem C6-aromatischen Carbocyclus, einem C5-C6-aromatischen Heterocyclus, der ein oder mehrere Heteroatome enthält, ausgewählt aus der Gruppe bestehend aus O, S und N, und einem C6-aromatischen Carbocyclus oder einem C5-C6-aromatischen Heterocyclus, der mit einem oder mehreren anderen Ringen fusioniert ist.
R1 ist -H, -OH, eine aliphatische Gruppe, -O-(aliphatische Gruppe), -O-(substituierte aliphatische Gruppe), -SH, -S-(aliphatische Gruppe), -S-(substituierte aliphatische Gruppe), -OC(O)-(aliphatische Gruppe) oder -O-C(O)-(substituierte aliphatische Gruppe);
R2 ist eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische Gruppe, eine substituierte aromatische Gruppe, eine Benzylgruppe, eine substituierte Benzylgruppe, eine nicht-aromatische heterocyclische Gruppe oder eine substituierte nicht-aromatische heterocyclische Gruppe;
Z ist:
worin
X1 ist -CH2-CH2-, -CH2-S-, -CH2-O-, -CH2-NRc-, -CH2-SO-, -CH2-S(O)2-, -CH=CH-, oder -CO-NRc-; worin
Rc ist eine aliphatische Gruppe, eine substituierte aliphatische Gruppe, eine aromatische
Gruppe, eine substituierte aromatische Gruppe, eine Benzylgruppe oder eine substituierte
Benzylgruppe;
Ring A und Ring B sind unabhängig von einander substituiert oder unsubstituiert.
ou ses sels physiologiquement acceptables,
où :
n est un entier de un à quatre;
M est >CR1R2;
R1 est -H, -OH, un groupement aliphatique, -O-(groupement aliphatique), -O-(groupement aliphatique substitué), -SH, -S-(groupement aliphatique), -S-(groupement aliphatique substitué), -OC(O)-(groupement aliphatique), -O-C(O)-(groupement aliphatique substitué), -C(O)O-(groupement aliphatique), -C(O)O-(groupement aliphatique substitué), -CN, -COOH, -CO-NR3R4 or -NR3R4; ou bien R1 est une liaison covalente entre l'atome de cycle M et un atome de carbone adjacent dans le cycle qui contient M;
R2 est -OH, un groupement acyle, un groupement acyle substitué, -NR5R6, un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué, un groupement benzyle, un groupement benzyle substitué, un groupement hétérocyclique non aromatique, ou un groupement hétérocyclique non aromatique substitué;
R3, R4, R5 et R6 sont indépendamment -H, un groupement acyle, un groupement acyle substitué, un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué, un groupement benzyle, un groupement benzyle substitué, un groupement hétérocyclique non aromatique ou un groupement hétérocyclique non aromatique substitué; ou
R1, R2, R3 et R4 ou R5 et R6, pris conjointement avec l'atome auquel ils sont fixés, forment un cycle hétérocyclique non aromatique, substitué ou non substitué;
ledit groupement acyle est un carbonyle aliphatique, un carbonyle aromatique, un sulfonyle aliphatique ou un sulfonyle aromatique;
Z a la formule :
dans laquelle :
X1 est -S-, -CH2, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2, -CH2-O-, -NRc-CH2-, -CH2-NRc,- -SO-CH2-, -CH2-SO-, -S(O)2-CH2, -CH2-S(O)2, -CH=CH-, -NRcCO- ou -CO-NRc-;
Rc est -H, un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué, un groupement benzyle ou un groupement benzyle substitué;
le cycle A et le cycle B sont indépendamment substitués ou non substitués; ledit groupement aliphatique substitué comprend un ou plusieurs substituants choisis dans le groupe constitué d'un groupement électro-attracteur, halo, azido, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2-NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21-R22, -(O)u-(CH2)t-NHC(O)OR20, -Q-H, -Q-(groupement aliphatique), -Q-(groupement aliphatique substitué), -Q-(aryle), -Q-(groupement aromatique), -Q-(groupement aromatique substitué), -Q-(CH2)p-(groupement aromatique substitué ou non substitué), -Q-(groupement hétérocyclique non aromatique), -Q-(CH2)p-(groupement hétérocyclique non aromatique), oxo, époxy, hétérocycle non aromatique, benzyle, benzyle substitué, groupement aromatique et groupement aromatique substitué;
lesdits groupement benzyle substitué, groupement aromatique substitué et le cycle A et le cycle B, lorsqu'ils sont substitués, comprennent un ou plusieurs substituants choisis dans le groupe constitué d'un groupement électro-attracteur, halo, azido, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino,-(O)u-(CH2)t-C(O)OR20, -(O)u(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)-O-R20, -Q-H, -Q-(groupement aliphatique) -Q-(groupement aliphatique substitué), -Q-(aryle), -Q-(groupement aromatique), -Q-(groupement aromatique substitué), -Q-(CH2)p-(groupement aromatique substitué ou non substitué), -Q-(groupement hétérocyclique non aromatique), -Q-(CH2)p- (groupement hétérocyclique non aromatique) un groupement aliphatique et un groupement aliphatique substitué; ledit groupement hétérocyclique non aromatique substitué comprend un ou plusieurs substituants choisis dans le groupe constitué d'un groupement électro-attracteur, halo, azido, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20,-(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22, -(O)u-(CH2)t-NHC(O)O-R20, -Q-H, -Q-(groupement aliphatique), -Q-(groupement aliphatique substitué), -Q-(aryle), -Q-(groupement aromatique), -Q-(groupement aromatique substitué) -Q-(CH2)p-(groupement aromatique substitué ou non substitué), -Q-(groupement hétérocyclique non aromatique), -Q-(CH2)p-(groupement hétérocyclique non aromatique), un groupement aliphatique, un groupement aliphatique substitué, =O, =S, =NH, =N(aliphatique), =N(aromatique) et =N (aromatique substitué);
R20, R21 et R22 sont indépendamment -H, un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué, un groupement hétérocyclique non aromatique, -NHC(O)-O- (groupement aliphatique) -NHC(O)-O-(groupement aromatique) ou -NHC(O)-O-(groupement hétérocyclique non aromatique); ou
R21 et R22, pris conjointement avec l'atome d'azote auquel ils sont fixés, forment un cycle hétérocyclique non aromatique;
t est un entier de zéro à trois;
u vaut zéro ou un;
p vaut un à cinq;
Q est -O-, -S-, -S(O), -S(O)2, -OS(O)2, -C(O), -OC(O)-, -C(O)O-, C(O)C(O)-O-, -O-C(O)C(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -NH-C(O)-NH-, -S(O)2NH-, -NHS(O)2-N(R23)-, -C(NR23)NHNH-, NHNHC(NR23)-,
-NR24C(O)- ou -NR24S(O)2;
R23 est -H, un groupement aliphatique, un groupement benzyle, un groupement aryle ou un groupement hétérocyclique non aromatique;
R24 et R25 sont indépendamment -H, -OH, un groupement aliphatique, un groupement aliphatique substitué, un groupement benzyle, un groupement aryle ou un groupement hétérocyclique non aromatique; ledit groupement aliphatique est un hydrocarbure en C1 à C20 saturé ou insaturé;
ledit groupement électro-attracteur est un alkylimino, un alkylsufonyle, un carboxamido, un ester d'alkyle carboxylique, -CH=NH ou -NO2;
l'hétérocycle dudit groupement hétérocyclique non aromatique est un cycle non aromatique de 5 à 8 éléments qui contient un ou plusieurs hétéroatomes choisis dans le groupe constitué de O, N et S; et
ledit groupement aromatique est choisi dans le groupe constitué d'un carbocycle aromatique en C6, d'un hétérocycle aromatique en C5 à C6 comprenant un ou plusieurs hétéroatomes choisis dans le groupe constitué de O,S et N et d'un carbocycle aromatique en C6 ou d'un hétérocycle aromatique en C5 à C6 qui est fusionné avec un ou plusieurs autres cycles.
R20, R21 ou R22 sont indépendamment -H, un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué ou un groupement hétérocyclique non aromatique; ou
R21 et R22, pris conjointement avec l'atome d'azote auquel ils sont fixés, forment un cycle hétérocyclique non aromatique;
u vaut zéro ou un; et
t est un entier de zéro à trois.
dans laquelle :
R40 est -OH, un halogène, un groupement aliphatique, un groupement aliphatique substitué, -NR24R25, Q- (groupement aliphatique), Q-(groupement aliphatique substitué), -O-(groupement aliphatique), -O-(groupement aliphatique substitué), -O-(groupement aromatique), -O-(groupement aromatique substitué), un groupement électro-attracteur, - (O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 ou -(O)u-(CH2)t-NHC(O)O-R20;
R20, R21 ou R22 sont indépendamment -H, un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué ou un groupement hétérocyclique non aromatique; ou
R21 et R22, pris conjointement avec l'atome d'azote auquel ils sont fixés, forment un cycle hétérocyclique non aromatique;
Q est -NR24C(O)- ou -NR24S(O)2-;
R24 et R25 sont indépendamment -H, -OH, un groupement aliphatique ou un groupement aliphatique substitué;
u vaut zéro ou un; et
t est un entier de zéro à trois.
et leurs sels physiologiquement acceptables.
ou ses sels physiologiquement acceptables, dans lesquels :
n est un entier de un à quatre;
M est >CR1R2;
R1 est -H, -OH, un groupement aliphatique, -0-(groupement aliphatique), -O-(groupement aliphatique substitué), -SH, -S-(groupement aliphatique), -S-(groupement aliphatique substitué), -OC(O)-(groupement aliphatique), -O-C(O)-(groupement aliphatique substitué), -C(O)O-(groupement aliphatique), -C(O)O-(groupement aliphatique substitué),-CN,-COOH,-CO-NR3R4 ou -NR3R4;
R2 est -OH, un groupement acyle, un groupement acyle substitué, -NR5R6, un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué, un groupement benzyle, un groupement benzyle substitué, un groupement hétérocyclique non aromatique ou un groupement hétérocyclique non aromatique substitué;
R3, R4, R5 et R6 sont indépendamment -H, un groupement acyle, un groupement acyle substitué, un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué, un groupement benzyle, un groupement benzyle substitué, un groupement hétérocyclique non aromatique ou un groupement hétérocyclique non aromatique substitué; ou
R1 et R2, R3 et R4 ou R5 et R6, pris conjointement avec l'atome auquel ils sont fixés, forment un cycle hétérocyclique ou carbocyclique non aromatique substitué ou non substitué;
ledit groupement acyle est un carbonyle aliphatique, un carbonyle aromatique, un sulfonyle aliphatique ou un sulfonyle aromatique;
Z a pour formule :
dans laquelle :
X1 est -S-, -CH2, -CH2CH2-, -CH2-S-, -S-CH2, -O-CH2-, -CH2-O-, -NRc-CH2, -CH2-NRc-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NRc-CO- ou -CO-NRc-;
Rc est -H, un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué, un groupement benzyle ou un groupement benzyle substitué; le cycle A et le cycle B sont indépendamment substitués ou non substitués; ledit groupement aliphatique substitué comprend un ou plusieurs substituants choisis dans le groupe constitué d'un groupement électro-attracteur, halo, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR30, -(O)u-(CH2)t-C(O)-NR21R22, -Q-H, -Q-(groupement aliphatique), -Q-(groupement aliphatique substitué), -Q-(aryle), -Q-(CH2)p-(groupement aromatique substitué ou non substitué), -Q-(groupement hétérocyclique non aromatique), -Q-(CH2)p-(groupement hétérocyclique non aromatique), oxo, époxy, hétérocycle non aromatique, benzyle, benzyle substitué, un groupement aromatique et un groupement aromatique substitué;
lesdits groupement benzyle substitué, groupement aromatique substitué et le cycle A et le cycle B lorsqu'ils sont substitués comprennent un ou plusieurs substituants choisis dans le groupe constitué d'un groupement électro-attracteur, halo, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-C(O)-NR21R22, -Q-H, -Q-(groupement aliphatique), -Q-(groupement aliphatique substitué), -Q-(aryle), -Q-(CH2)p-(groupement aromatique substitué ou non substitué), -Q-(groupement hétérocyclique non aromatique), -Q-(CH2)p-(groupement hétérocyclique non aromatique), groupement aliphatique et groupement aliphatique substitué;
ledit groupement hétérocyclique non aromatique substitué comprend un ou plusieurs substituants choisis dans le groupe constitué d'un groupement attracteur d'électrons, halo, -CN, -COOH, -OH, -CONR24R25, -NR24R25, -OS(O)2NR24R25, -S(O)2NR24R25, -SO3H, -S(O)2NH2, guanidino, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-C(O)-NR21R22, -Q-H, -Q-(groupement aliphatique), -Q-(groupement aliphatique substitué), -Q-(aryle), -Q-(CH2)p-(groupement aromatique substitué ou non substitué), -Q-(groupement hétérocyclique non aromatique), -Q-(CH2)p-(groupement hétérocylique non aromatique), groupement aliphatique, groupement aliphatique substitué, =O, =S, =NH, =N(aliphatique), =N(aromatique) et =N(aromatique substitué);
R20, R21 et R22 sont indépendamment -H, un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué, -NHC(O)-O-(groupement aliphatique), -NHC(O)-O-(groupement aromatique) ou -NHC(O)-O-(groupement hétérocyclique non aromatique); ou
R21 et R22, pris conjointement avec l'atome d'azote auquel ils sont fixés, forment un cycle hétérocyclique non aromatique;
t est un entier de zéro à trois;
u vaut zéro ou un;
p vaut un à cinq;
Q est -O-, -S-, -S(O)-, -S(O)2-, -OS(O)2-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)C(O)-O-, -O-C(O)C(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, NH-C(O)-NH-, -S(O)2NH-, -NHS(O)2, -N(R23)-C(NR23)NHNH-, -NHNHC(NR23)-;
R23 est -H, un groupement aliphatique, un groupement benzyle, un groupement aryle ou un groupement hétérocyclique non aromatique;
ledit groupement aliphatique est un hydrocarbure en C1 à C20 saturé ou insaturé;
ledit groupement électro-attracteur est un alkylimino, un alkylsulfonyle, un carboxamido, un ester d'alkyle carboxylique, -CH=NH ou NO2;
l'hétérocycle dudit groupement hétérocyclique non aromatique est un cycle non aromatique de 5 à 8 éléments qui contient un ou plusieurs hétéroatomes choisis dans le groupe constitué de O, N, et S; et
ledit groupement aromatique est choisi dans le groupe constitué d'un carbocycle aromatique en C6, d'un hétérocycle aromatique en C5 à C6 comprenant un ou plusieurs hétéroatomes choisis dans le groupe constitué de O, S et N, et d'un carbocycle aromatique en C6 ou d'un hétérocycle aromatique en C5 à C6 qui est fusionné avec un ou plusieurs autres cycles.
R1 est -H, -OH, un groupement aliphatique, -O-(groupement aliphatique), -O-(groupement aliphatique substitué), -SH, -S-(groupement aliphatique), -S-(groupement aliphatique substitué), -OC(O)-(groupement aliphatique) ou -O-C(O)-(groupement aliphatique substitué);
R2 est un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué, un groupement benzyle, un groupement benzyle substitué, un groupement hétérocyclique non aromatique ou un groupement hétérocyclique non aromatique substitué;
Z a pour formule :
dans laquelle :
X1 est -CH2-CH2-, -CH2-S-, -CH2-O, -CH2-NRc, -CH2-SO-, CH2-S(O)2-, -CH=CH- ou -CO-NR2-; où
Rc est un groupement aliphatique, un groupement aliphatique substitué, un groupement aromatique, un groupement aromatique substitué, un groupement benzyle ou un groupement benzyle substitué; et
le cycle A et le cycle B sont indépendamment substitués ou non substitués.